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ABSTRACT 
 
Glioblastoma is a very invasive and metastatic cancer with low patient survival-rate 
and high resistance to current treatment. Matrix metalloproteinase 2 (MMP2) is 
upregulated in glioblastoma multiforme (GBM) and its high expression is directly 
correlated with invasion and metastasis of GBM cells. Annexin A2 is involved in 
angiogenesis, and it is overexpressed in GBM. MMP2 and annexin A2 are potential 
targets for effective glioma therapy. Chlorotoxin is a promising toxin peptide for 
glioma targeted therapy. Chlorotoxin decreased migration and metastasis of GBM 
cells, although mechanism of action of the toxin is unclear due to the complicated 
nature of GBM, slow and costly experiments and challenging techniques. The 
relationship of chlorotoxin binding to both MMP2 and annexin A2 is controversial and 
further work is needed to clarify a complex situation. Chlorotoxin-like short toxins are 
homologous peptides that may also have potential therapeutic effects for glioma.  
In this study homology modelling was used to predict 3D models of chlorotoxin-like 
short toxins. Stereochemical quality estimation of 3D models was performed with 
QMEAN, Z-Score and Procheck server. ClusPro docking programme was used to 
dock 3D structures of chlorotoxin and chlorotoxin homologues with their putative 
binding partners MMP2 and annexin A2 to provide a first step to understand the 
mechanism of action of the toxin. Chlorotoxin shows binding interaction with both 
MMP2 and annexin A2. Chlorotoxin-like short toxins also showed stronger binding 
interaction with activated MMP2 than annexin A2. The positively charged surface of 
chlorotoxin is mainly involved in interaction with MMP2. All three chlorotoxin-like 
short toxins bind to a similar site on MMP2 but on separate sites on annexin A2 
hence suggesting the significance of observed interaction between chlorotoxin and 
MMP2. 
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1 INTRODUCTION 
1.1 Glioblastoma. 
Glioma is a lethal malignant primary brain cancer (Bayat et al., 2016). Glioma 
consists of several subtypes including astrocytoma, oligodendroglioma, 
ependymoma and glioblastoma multiforme (Stupp et al., 2014). Glioblastoma 
multiforme (GBM) is the highest grade and most malignant type of glioma (Blume et 
al., 2013; Lee et al., 2015). Current treatment includes surgical resection of 
cancerous tissues, where possible, as well as radiotherapy followed by 
chemotherapy with the DNA alkylating agent temozolomide (Yin et al., 2007; Ganau 
et al., 2015). However, the median survival time is approximately 16 months with 
current treatment and there is a 5-year survival time of 5% (Ganau et al., 2015). 
Surgery and chemotherapy are challenging due to the diffusive and metastatic 
nature of glioma (Kesari et al., 2011, Sun et al., 2012). Moreover, many 
chemotherapeutic agents cannot cross the blood brain barrier (Blume et al., 2013; 
Ramirez et al., 2013).   
Tumour cells secrete proteolytic enzymes such as matrix metalloproteinases (MMPs) 
which degrade components of the extracellular matrix (ECM) and then invade 
surrounding healthy brain tissues (Madsen et al., 2015). It is crucial to understand 
underlying factors of GBM metastasis for effective anticancer therapy and to 
increase patient survival-time (Yan et al., 2011). GBM metastasis is a very 
complicated process as GBM cells are very diffusive in nature and exhibit tumour 
heterogeneity (Soeda et al., 2015). Several proteases play important role in 
facilitating cancer cell adhesion, migration and metastasis (Wang et al., 2003). 
Adhesion of the GBM cells to the ECM occurs which provides traction for cancer cell 
mobility in a liquid filled 3D environment (Wang et al., 2003). Glioma cells and 
endothelial cells secrete MMPs including MMP2, MMP9 and MT1-MMP which play 
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an important role in the degradation of the ECM of brain tissue (Goldbrunner et al., 
1999). Ion fluxes generated by K+ and Cl- ion channels remarkably alters morphology 
of GBM cells by forming membrane protrusions and changes the cell volume via loss 
of water and osmotic pressure, helping GBM cells to shrink and squeeze through the 
ECM and metastasize surrounding tissues (Soroceanu et al., 1999; Turner et al., 
2014). Cell surface receptors such as integrins and the hyaluronate receptor CD44 
are involved in GBM cell adhesion (Goldbrunner et al., 1999). GBM adhesion to the 
ECM occurs via integrin αVβ3 as well as αVβ5 and the process may have rearranged 
cytoskeleton via cytoplasmic mediators such as focal adhesion kinase (FAK) and 
Pyk2. These integrin facilitate cancer cell mobility and invasion (Rupp et al., 2008). 
Integrin αVβ3 can directly bind to MMP2 and increases enzyme concentration on 
GBM cell surface thus enabling tumour cells to regulate MMP2 function and 
metastasise surrounding brain tissues (Munaut et al., 2003; McFerrin et al., 2006). 
Abnormal angiogenesis is also associated with tumour metastasis (Das and 
Marsden, 2013). GBM is one of the most vascular-rich tumour containing blood 
vessels that are highly permeable, with abnormal endothelial wall, twisted with an 
irregular pattern (Yi et al., 2016).  Annexin A2 is involved in angiogenesis and 
metastasis of GBM.  
 
1.1.1 Matrix metalloproteinases 
Matrix-metalloproteinases (MMPs) are zinc-dependent endopeptidases involved in 
the degradation of the extracellular matrix (Nagase and Woessner, 1999). The 
activity of MMPs is highly regulated under normal conditions because they are 
involved in many physiological processes such as tissue remodelling, angiogenesis, 
wound healing, embryogenesis, nerve growth and apoptosis (Rahme et al., 2015). In 
contrast, MMPs are overexpressed and unregulated in pathological conditions such 
as cancer and cardiovascular diseases (Nagase and Woessner, 1999). Tissue-
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inhibitor of metalloproteinases (TIMPs) are natural inhibitors of MMPs that control 
their activity (Nakopoulou et al., 2003).  
MMPs are secreted as latent zymogens (Strongin et al., 1995), In order to activate 
MMPs, the activation peptide is cleaved which exposes the catalytic site (Morgonuva 
et al., 1999; Hur et al., 2000). In the activation of MMP2, MT1-MMP (MMP14) forms 
a complex with TIMP2 on the cell surface (Gingras et al., 2000). The C-terminal 
domain of proMMP2 binds to TIMP2, forming a MT1-MMP/TIMP2/proMMP2 
complex. Activation is mediated by another free MT1-MMP which interacts with 
complexed MT1-MMP via its C-terminal domain. MT1-MMP can cleave its substrate 
but cannot activate proMMP2 without TIMP2 (Bernardo and Fridman, 2003). 
 
1.1.2 High expression of MMP2, MMP9 and Annexin A2 in GBM 
MMP2 and MMP9 are involved in the degradation of ECM components including 
collagen and other matrix substrates (Liotta et al., 1980; Yong et al., 2001). Enzyme-
linked immunosorbent assay and gelatin zymography showed overexpression of 
MMP2 in GBM compared to low-grade glioma (Sawaya et al., 1996; Choe et al., 
2002). Furthermore, immunohistochemical technique showed the localisation of 
MMP2 and MMP9 in only glioma cells and its blood vessels (Sawaya et al., 1996; 
Ramachandran et al., 2017). MMP2 was highly expressed in GBM tissue samples as 
well as all transformed cell lines but not in healthy brain tissues (Deshane et al., 
2003; Kargiotis et al., 2008; Hagemann et al., 2010; Rahme et al., 2015).  
Molecular mechanism of GBM invasion and metastasis is very complex (Kleber et al. 
2008). Overexpression of MMP2 regulated by various molecular cascades leads to 
the invasion of GBM cells in healthy brain tissues (Hagemann et al., 2010). 
Interleukin-6 (IL-6), IL-10 and Th2 cytokine activates signal transducer and activator 
of transcription 3 (STAT3), a transcription factor which facilitates glioma invasion and 
metastasis (Brantley et al., 2008; Vasquez-Dunddel, 2013). STAT3 regulates and -
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promotes overexpression of MMP2 including proteins such as cyclin D1, a cell cycle 
progression regulator (Peng2016).  
GBM cells use MMP2 to initiate cancer cell invasion and metastasis regulated by 
CD95/CD95L signalling pathway. CD95 ligand (CD95L) is a natural ligand for CD95 
cell surface receptor of tumour necrosis receptor family (Peter et al., 2015). CD95L 
induces apoptosis by initiating death-inducing signalling pathways by recruiting pro-
apoptotic factors including caspase-8 to CD95 (Kleber et al., 2008). However, in 
apoptotic resistant GBM cells, CD95L induce tumorigenesis mediated by MMP2 via 
activation of Src-PI3K signalling pathway.    
Transcription of MMP2 and MMP9 is initiated by β-catenin translocation into the 
nucleus and the process is initially induced by CD95 ligand (CD95L). CD95L allows 
binding of the Src family kinase (SFK; nonreceptor tyrosine kinase) member Yes and 
p85 subunit of phosphatidylinositol 3-kinase (PI3K) to CD95 resulting in the 
activation of AKT, a serine-threonine protein kinase also known as protein kinase B 
(PKB). Active AKT results in phosphorylation and inhibition of glycogen synthase 
kinase 3-β (GSK3-β), initiating translocation of β-catenin into the nucleus hence 
subsequent expression of MMPs particularly MMP2 (Kleber et al., 2008). 
Furthermore, MMP2 upregulation and invasion of GBM was mediated by forkhead 
transcription factor (FoxM1B) as well as insulin-like growth factor binding protein-2 
(IGFBP2) (Wang et al., 2003; Levitt et al., 2005). In human GBM specimen, FoxM1B 
was upregulated as well as elevated MMP2 expression was observed (Dai et al., 
2007). In addition, FoxM1B transformed normal astrocytes to GBM via process that 
degraded phosphatase and tensin homologue (PTEN) and activated AKT (Dai et al., 
2010). The low-density lipoprotein receptor-related protein 1 also elevated MMP2 
and MMP9 in an extracellular signal-regulated kinase (ERK) dependent pathway 
(Song et al., 2009). This suggest role of MMP2 in signal transduction and glioma 
proliferation and invasion, hence targeting MMP2 is a potential therapeutic strategy. 
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A recent study showed that glioma influence microglia activation and initiates 
microglial infiltration which induces activation of the oncogenes and production of 
cytokines. MT1-MMP activated by this mechanism degrades the ECM and facilitates 
tumour progression (Resende et al., 2016). Interleukin-1 (IL-1) production also 
activates STAT3 as well as MMP2 upregulation in glioblastoma which leads to 
invasion and metastasis (Tarassishin et al.,2014). Angiogenesis is promoted by IL-1 
production in glioma cells as IL-1 induced glioma secretosome that contains factors 
which leads to vascular angiogenesis (Tarassishin et al., 2014). Tumour associated 
endothelial cells mediate secretion of MMP2 thus contributing to aggressive 
proliferation of GBM cells and establishment of a hostile microenvironment (Soda et 
al., 2011). Annexin A2 (AnxA2), a Ca2+ dependent, phospholipid-binding protein, is 
localised at the surface of endothelial cells as well as glioma cells (Tatenhorst et al., 
2006). AnxA2 is overexpressed in many cancers including glioma, pancreatic cancer, 
colorectal and breast cancer (Kesavan et al., 2010). AnxA2 is involved in 
angiogenesis and more highly expressed in high-grade glioma than in low-grade 
glioma (Onishi et al., 2015). AnxA2 is involved in migration of the vascular 
endothelial cells and formation of the abnormal tumour vasculature in high-grade 
glioma (Kesavan et al., 2010). Recently, molecular targeted therapy is being 
considered as an effective anti-cancer therapy (Wang et al., 2015).  
 
1.1.2 Biochemical studies and structure prediction, based on amino acid 
sequencing and cDNA cloning.  
 
Full-length human MMP2 (gelatinase A) is a 72kDa enzyme involved in the 
degradation of collagens and gelatins (Morgunova et al., 1999). An active 
intermediate of the MMP2 is a 64 kDa enzyme which is subsequently cleaved to form 
the stable 62kDa active peptide (Lafleur et al., 2001). The full-length MMP2 
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comprises 660 amino acids (AAs) including a signal peptide (residues 1-29). The 
activation peptide of MMP2 (residues 30-109) contains the cysteine-switch motif 
PRCGVPD (Fig 1) which is important for keeping MMP2 in its inactive form. The 
catalytic region (residues 110-465) of MMP2 encompasses a catalytic domain and 
three repeats of a fibronectin type-II (Fib-II) domain, inserted into the catalytic 
domain. The catalytic domain of MMP2 has one catalytic Zn2+ ion and one structural 
Zn2+ ion as well as 3 Ca2+ ions. The Fib-II domains are important invcollagen, elastin 
and laminin binding as well as gelatin (Ghermann et al., 2002). The Fib-II domain 1 
consists of 63 AAs, the Fib-II domain 2 consists of 60 AAs and the Fib-II domain 3 
consists of 72 AAs. The hemopexin-like domain (residues 466-660) is linked to the 
catalytic domain via a hinge peptide (Fig1). The hemopexin-like domain consists of 
four subunits and its subunits 1 and 4 are connected via a disulphide bond (Fig 1).  
 
 
Figure 1. Domain structure of the MMP2. The signal peptide is indicated as ‘Pre’, 
activation peptide as ‘Pro’ which contains the cysteine-switch motif PRCGVPD. The catalytic 
domain contains Zn2+ ions (coloured turquoise). The Fib-II domains are represented by pink 
circles included in the catalytic region. The hemopexin-like domain (yellow) linked to the 
catalytic domain via a hinge peptide (dark blue). The 72kDa enzyme represents full-length 
inactivated MMP2 whereas 64kDa represents intermediate active MMP2. Red arrow 
indicates cleavage site to form 64kD MMP2 (Kandasamy et al., 2010).  
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1.1.4. 3D structures of MMP2 and its various domains.  
A number of 3-dimensional (3D) structures of MMP2 have been determined 
experimentally by X-ray diffraction and nuclear magnetic resonance (NMR). These 
structures include full-length MMP2 (PDB code: 1CK7), the catalytic domain of 
MMP2 (PDB code 1QIB), first Fib-II domain (PDB code: 1KS0), second Fib-II domain 
(PDB code: 1CXW), third Fib-II domain (PDB code: 1J7M) and the hemopexin-like 
domain (PDB code: 1RTG).   
 
1.1.4.1 Full-length human MMP2 (Gelatinase A) chain A.   
The full-length human MMP2 3D structure was experimentally determined by X-ray 
diffraction to 2.8Å resolution by Morgunova et al. (1999) (PDB code: 1CK7) and 
consists of 631 residues corresponding the full-length sequence of the protein 
excluding the signal peptide (residues 1-29).  
The protein from which the structure of proMMP2 was derived has a Glu404Ala 
mutation (Morgunova et al., 1999). Glu404 is involved in the catalytic activity of 
MMP2 (Hangauer et al., 1984) and was replaced with alanine to allow crystallisation 
of MMP2 and provide stability against autoproteolysis. This mutation did not affect 
the architecture of the catalytic site of protein (Morgunova et al., 1999).   
The activation peptide of 1CK7 consists of 3 α-helices as well as short loops. A 
specific cleavage site for proteases, called the ‘bait-region’, is present at the 
connecting loop between helix 1 and helix 2 of the activation peptide (Fig 1.1). The 
activation peptide has an extended loop after helix-3 which contains the conserved 
cysteine-switch motif, interacting with the active zinc site of the catalytic domain (Fig 
1.1). 
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Figure 1.1 3D structure of proMMP2 (72kDa). The MMP2 (PDB code: 1CK7) activation 
peptide (green) contains 3 α-helices and connecting loops as shown in Fig 1.1. The 
protease-susceptible bait-region and cysteine-switch is represented by red asterisk and red 
triangle respectively. The catalytic domain (grey), three Fib-II domains (red) as well as 
hemopexin domain (blue) are shown. The Zn2+ ions are orange spheres and Ca2+ ions are 
purple (Sela-Passwell et al., 2009).  
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1.1.4.2 3D structures of various regions of MMP2.  
The 3D structures of various regions of MMP2 have already been determined by X-
ray crystallography and NMR studies (Visse and Nagase, 2003). The crystal 
structure of the catalytic domain of MMP2 was experimentally determined by X-ray 
diffraction at 2.8 Å resolution by Dhanaraj et al., (1999) (PDB code: 1QIB). The 
catalytic domain contains 3 Ca2+ ions as well as one structural Zn2+ ion and one 
catalytic Zn2+ ion where three histidine residues (H403, H407 and H413) and a water 
molecule which is also found in the crystal structure, all interact with the catalytic 
Zn2+ ion (Dhanaraj et al., 1999).  
The 1QIB protein was expressed in E. coli and the amino acid sequence of the 
fibronectin domains was deleted during expression and crystallisation of 1QIB (Fig 
1.2a). The 3D structure of 1QIB consists of 3 α-helices, 5 stranded β-sheets and 
connecting loops.  The catalytic domain has a specificity pocket S1’ pocket located at 
the right side of the CAT-Zn represented by stick residues (Fig 1.2a) as well as a 
substrate binding-cleft formed by the β-sheet IV, helix-B followed by an extended 
peptide region (Fig 1.2a).  
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Fig 1.2. 3D structures of various regions of MMP2. (a). The 3D structure of the catalytic 
domain contains 3 α-helices (indicated as A to C) and 5 β-sheets (indicated as I-V). β-sheets 
and α -helices of 1QIB are arranged as ‘NH2-I-A-II-III-IV-V-B-C-COOH’. The Zn2+ ions are 
shown as pink spheres and Ca2+ions are shown as blue spheres (b) three Fib-II domains of 
the MMP2, (c) the hemopexin-like domain of MMP2 consists of 4 propeller-like blades of β-
sheets with a disulphide present between blade I and IV indicated with yellow lines (Visse 
and Nagase, 2003).  
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1.1.4.3 The Fibronectin Domains of the MMP2  
MMP2 consists of an array of three Fib-II domains which bind to gelatin, elastin, 
collagen type I and IV and laminin (Ghermann et al., 2002). The 3D structures of the 
Fib-II domains 1, 2 and 3 were determined by NMR spectroscopy (Briknarova et al., 
1999 and Briknarova et al., 2001; Ghermann et al., 2002). The 3D structure of third 
Fib-II domain (PDB code: 1J7M) has a E11G mutation verified by DNA sequencing. 
NMR spectroscopy showed that the codon for glutamic acid at position 11 (GAA) in 
the 1J7M expression plasmid mutated to GGA (Gly amino acid) during plasmid 
propagation. This mutation did not affect overall 3D structure (Briknarova et al., 
2001). 
The Fib-II domains are inserted between the 5th β-sheet and 2nd α-helix of the CAT 
domain. Each Fib-II domain consists of a pair of β-sheets and a small helix stabilised 
by two disulphide bonds that is indicated by yellow sticks (Fig 1.2b). The hydrophobic 
pockets formed by the β-sheets of the fibronectin domains are involved in substrate 
(gelatin) binding hence determining substrate specificity (Murphy and Knauper, 1997; 
Ghermann et al., 2002).  
 
1.1.4.4 The C-terminal domain of MMP2.  
The 3D crystal structure of the C-terminal domain (hemopexin-like domain) of MMP2 
was determined by X-ray diffraction at 2.6 Å resolution by Gohlke et al., (1996) (PDB 
code: 1RTG). Amino acid residues start from 451 to 660 with 33% coverage of 
gelatinase A. There are 2 Ca+ co-factors and 1 Cl- ion bound to the structure. The 
structure (1RTG) consists of 4 bladed propeller-like discs as shown in Fig 1.2c, 
where blade I and IV are connected via a disulphide bond (Fig 1.2c).  
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1.1.5 Activation of proMMP2, the Cysteine Switch.  
MMP2 is secreted as an inactive zymogen (Nagase and Woessner., 1999). An 
extended loop after helix-3 of the activation peptide contains a conserved cysteine. 
The sulfhydryl group of this cysteine co-ordinates with the zinc ion of the CAT 
domain keeping MMP2 in its zymogen form (Bescond et al., 1999).  
Inactive proMMP2 (72kDa) is activated when the proteinase-sensitive ‘bait region’ 
between helix-1 and helix-2 of the activation peptide is cleaved by proteases such as 
plasmin, which disrupts the Cys-Zn coordination (Fig 1.3). Though only a fragment of 
the activation peptide is cleaved, the rest of the activation peptide is cleaved by the 
MMP intermediate or by other active MMPs which activates MMP2. Finally, a fully 
activated MMP2 (62kDa) is generated (Fig 1.3).   
ProMMP2 can be activated by thiol modifying agents such as 4-aminophenylmercuric 
acetate (APMA), N-ethylmaleimide (NEM) as well as sodium dodecyl sulphate 
(SDS), oxidised glutathione (GSSG) and hypochlorous acid (HOCl) (Chakraborti et 
al., 2003; Nagase et al., 2006). The thiol-modifying agents disrupt the Cys-Zn 
interaction by modifying the sulfhdryl (SX) group exposing the catalytic site (Fig 1.3). 
The initial cleavage occurs within the activation peptide region and this reaction is 
intramolecular; this is followed by removal of the rest of the activation peptide, due to 
the intermolecular reaction of intermediate compounds (Nagase et al., 2006). 
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Figure 1.3. Cysteine switch mechanism. ProMMP2 can be activated chemically (bottom 
pathway) as well as by proteinases (top pathway). Black rectangle represents ‘bait region’ 
and ‘C’ represents the cysteine switch in propeptide. Sulfhydryl of cysteine is represented by 
‘SH’ in top pathway and ‘SX’ in bottom pathway. Thiol modifying agents such as AMPA and 
NEM as well as proteases such as plasmin, disrupt the Cys-Zn coordination exposing the 
catalytic site. MMP2 is fully activated after removal of the activation peptide by intermediate 
compounds (Visse and Nagase, 2003).  
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MMP2 can be activated biologically as well as chemically. MT1-MMP (MMP14) 
complexed with TIMP2 leads to activation of proMMP2 (Cao et al., 1995). The 
complex acts as a receptor for proMMP2; the N-terminal domain of TIMP2 binds to 
MT1-MMP on the cell surface, allowing the C-terminal domain to interact with 
proMMP2, then this is activated by another free MT1-MMP. Another free MT1-MMP 
interacts with the MT1-MMP, TIMP2, ProMMP2 complex and activates proMMP2 
(Fig 1.4) (Bernardo and Fridman, 2003). 
 
 
 
 
Figure 1.4. Activation of proMMP2 by MT1-MMP/TIMP2 complex. An active MT1-MMP 
(MT-1) complexed with TIMP2 on cell surface serves as a receptor for proMMP2 (pM-2). The 
hemopexin domains of two MT-1 (MMP14) on cell surface can interact to form a dimer. The 
C-terminal domain of pM-2 binds to MT-1/T-2 complex and the activation peptide binds to 
free MT-1 activating pM-2. MT-1 can cleave its substrate but cannot activate pM-2 without 
T2 (Visse and Nagase, 2003).  
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1.2 ANNEXIN A2 
1.2.1 Annexin A2 in GBM 
Annexin A2 (AnxA2) is a calcium-binding cytoskeletal protein which is localised at the 
surface of endothelial cells as well as glioma cells (Tatenhorst et al., 2006). It is more 
highly expressed in high-grade GBM than low-grade (Beckner et al., 2005; Zhai et 
al., 2011). GBM over-expression of AnxA2 is correlated with an increase in 
metastasis and abnormal angiogenesis of GBM cells by promoting degradation of 
the ECM, vascular endothelial cell migration and vascular remodelling (Zhao et al., 
2010). AnxA2 mediates glioma cell adhesion to endothelial cells and promotes 
production of angiogenic factors such as vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor (PDGF) thus promotes neovascularization and 
invasion (Maule et al., 2016). In glioblastoma specimen, multiple satellites of tumour 
cells containing dilated blood vessels were found in brain parenchyma near brain 
tumour centre (Onishi et al., 2015). Immunohistochemical and qRT-PCR studies 
showed high expression of AnxA2, VEGF and PDGF in glioblastoma cells. Moreover, 
staining intensity of VEGF and PDGF positively correlated with AnxA2 
overexpression hence suggesting AnxA2 role in regulating angiogenesis (Onishi et 
al., 2015).  
Moreover, surface biotinylation assay showed elevated AnxA2 expression on GBM 
cell surfaces and tumour associated endothelial cells (Kesavan et al., 2010). 
Reduced migration of GBM cells has been shown in an AnxA2 knockout mouse 
model (Tatenhorst et al., 2006). AnxA2 silencing by small-interfering RNA (siRNA) in 
human glioblastoma cell lines (U87MG and U373MG) also resulted in reduced 
migration (Zhao et al., 2011). AnxA2 regulates expression of VEGF through protein 
kinase C (PKC) signalling pathway and a positive feedback mechanism (Zhao et al., 
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2011). In AnxA2 depleted glioblastoma cells, expression of proangiogenic factors 
was inhibited (Bao et al., 2009).   
AnxA2 mediates the activation of a serine protease enzyme called plasmin (Sharma 
et al., 2007). Plasminogen activators such as tissue plasminogen activator (tPA) and 
urokinase plasminogen activator (uPA) convert the inactive plasminogen to active 
plasmin (Diaz et al., 2004). AnxA2 complexed with p11 serves as a co-receptor for 
tissue plasminogen activator (tPA) and plasminogen on the cell surface which 
mediates the conversion of the inactive plasminogen to plasmin (Valapala et al., 
2011). This process also induces endothelial cell and tumour cell mediated release 
of growth factors such as basic fibroblast growth factor (bFGF) and PDGF (Maule et 
al., 2016). Plasmin is involved in angiogenesis by fibrinolysis, degradation of the 
ECM components such as laminin, proteoglycans and fibronectin as well as 
activation of the proMMP2 (Tatenhorst et al., 2006; Lokman et al., 2011). Plasmin 
promotes angiogenesis by binding to integrin αVβ3 and facilitating endothelial cell 
migration (Tarui et al., 2002). This process is facilitated by high expression of (bFGF) 
as well as attracting human peripheral monocytes and degrading platelet aggregation 
(Tarui et al., 2002). All these pathological processes are important for AnxA2 
mediated angiogenesis and subsequent invasion and metastasis of GBM cells. This 
suggests that targeting AnxA2 would be an effective anti-cancer therapy and may 
improve patient survival (Ichikawa et al., 2014).  
 
1.2.1 Structure of Annexin A2. 
The 3D structure of AnxA2 was determined from X-ray diffraction studies by Shao et 
al., (2006). AnxA2 consists of a N-terminal ‘head-domain’ of  ̴ 33 amino acids and a 
highly conserved core motif of 31-338 amino acids, making a curve-shaped protein. 
The core motif of the carboxyl domain consists of four homologous repeats also 
called annexin repeats (I-IV); each repeat encompasses 70-80 residues, arranged in 
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a near-parallel shape (Fig 1.5b). All homologous repeats have a similar structure, 
each repeat consists of 5 α-helices and connective loops (Fig 1.5b). The N-terminal 
domain is involved in the tPA binding site whereas, the C-terminal domain is involved 
in calcium binding as well as phospholipid binding and F-actin binding (Jones et al., 
1992; Rety et al., 1999). 
 
Fig 1.5. Structure of AnxA2 protein. (a) Domain structure of AnxA2 where C-terminal core 
region is represented by pink cubes and N-terminal ‘head domain’ by blue rectangle. The 
NH2 terminus of AnxA2 is acetylated (b) 3D structure of AnxA2 (PDB code: 2HYW), four 
homologous annexin repeats are labelled and each repeat consists of 5 α-helices linked to 
each other via connective loops. Ca2+ ions are represented by black spheres (Lokman et al., 
2011; RCSB PDB databank). 
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MMP2 and AnxA2 are potential candidates for molecular targeted therapy for glioma 
because they are involved in GBM invasion, adhesion, angiogenesis and metastasis 
(Kling et al., 2016). GBM is resistant to surgery and chemotherapy due to its diffuse 
nature (Ramirez et al., 2013). Studies have shown that even low-grade glioma 
invade healthy brain tissues at a fast rate; it is therefore crucial to target these 
proteins to inhibit glioma metastasis and improve effectiveness of glioma treatment. 
A number of studies are under investigation to target MMP2 and AnxA2 thus inhibit 
GBM metastasis and increase survival-rate (Kesavan et al., 2010; Alam et al., 2010; 
Badiga et al., 2011; Ali et al., 2016).  
 
1.3 Chlorotoxin 
Chlorotoxin (Cltx) is a 36 amino acid peptide derived from venom of the scorpion (L. 
quinquestriatus) (DeBin et al., 1993). Cltx specifically binds to GBM and inhibits its 
invasion and metastasis without having an effect on healthy brain tissues 
(Soroceanu et al., 1998; Kovar et al., 2013; Butte et al., 2014). Cltx also binds to 
tumours of neuroectodermal origin such as small-cell lung carcinoma, melanoma, 
suggesting that it might be used to treat a range of cancers (Lyon et al., 2002). Cltx 
is in phase-III clinical trials for glioma treatment and is being used for diagnostic and 
imaging of glioma (Veiseh et al., 2007; Zhang et al., 2016).  
The 3D structure of Cltx was experimentally determined by NMR spectroscopy 
(Lippens et al., 1995). It has a compact structure comprised of 3 short anti-parallel β-
sheets tightly packed around an α-helix (Fig 1.6). The compact structure of Cltx is 
stabilised by four disulphide bonds linking the cysteine residues.   
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Figure 1.6. Primary structure and 3D structure of Cltx. (A) Cltx consists of 36 amino 
acids, the sequence contains 8 highly conserved cysteine residues (B) Ribbon structure of 
Cltx (PDB code: 1CHL), peptide consists of an alpha helix and 3 anti-parallel β-sheets 
connected with loops. Four disulphide bridges are present between highly conserved 
cysteines. β-sheets are coloured in blue and α-helix is coloured in red; disulphide bridges of 
the toxin are coloured in orange (Dardevet et al., 2015).   
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At first, chlorotoxin was believed to inhibit chloride fluxes by blocking small-
conductance chloride channels in epithelial cells (DeBin et al., 1993). Cltx was shown 
to bind selectively to glioma specific Cl- channels in acute slices of human gliomas 
(Ullrich et al., 1998). Later, studies showed that chlorotoxin specifically interacts with 
a lipid raft-anchored complex that contains MMP2, MT1-MMP, TIMP2 and chloride 
channels (ClC3) facilitating internalisation of the cell surface complex thus reducing 
glioma metastasis (Kesavan et al., 2010).  
Fortunately, Cltx is accessible to glioma cells as it can cross well defined blood brain 
barrier (BBB) or at least leaky blood brain tumour barrier (BBTB). Cltx was shown to 
diffuse deeply in glioma whereas specific antibodies were not able to cross BBB 
(Mamelak et al., 2007; Veiseh et al., 2009). Also, Cltx conjugated fluorescent dye 
Cy5.5 (Cy5.5-Cltx) labelled glioma cells without affecting toxin transport across the 
BBB in a transgenic mice model (Veiseh et al., 2007). 
Cltx specifically inhibited MMP2 activity but did not interact with either MMP1 and 
MMP9 which are expressed on the surface of glioma cells (Deshane et al., 2003). 
Cltx inhibited MMP2 activity via fluorescence resonance energy transfer (FRET) 
substrate assay and gelatin zymography (Alam et al., 2012). Inhibition of MMP2 
activity resulted in the prevention of glioma cell shrinkage and release from the ECM. 
Thus, reduced migration of GBM cells occurred through the extracellular space of 
brain tissue (McFerrin and Sontheimer 2006). Moreover, Cltx demonstrated a high 
affinity binding site and a low binding affinity site for radio-iodinated Cltx (125I-Cltx) 
suggesting more than one receptor for Cltx on the glioma cell surface (Soroceanu et 
al., 1998).   
A synthetic version of Cltx has been synthesized under the name of TM601 
(Kesavan et al., 2010). TM601 showed both anti-tumour activity against glioma and 
anti-angiogenic activity against human umbilical vein endothelial cell (HUVECs). 
TM601 is being used in phase-III clinical trials in the US. Radio-labelled TM601 
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(radioactive iodine 131I conjugated at Tyr29) is being used for diagnostic imaging and 
radiotherapy of glioma. Cltx-Cy5.5 is an infrared dye which is being used for imaging 
and surgical resection of glioma (Vieseh et al., 2007; Stroud et al., 2011).  
Cltx-conjugated nanoparticles are under investigation for glioma imaging, therapy 
and drug delivery (Hsiao et al., 2015; Han et al., 2016; Chen et al., 2016; Tamborini 
et al., 2016). 
To complicate the situation further, another target for Cltx was subsequently 
identified (Kesavan et al., 2010). Cltx was shown to have anti-angiogenic effects by 
binding to human umbilical vein endothelial cells (HUVECs) (Zhai et al., 2011). Cltx 
also binds to AnxA2 on glioma cells thus inhibiting migration and metastasis 
(Kesavan et al., 2010; Onishi et al., 2015). Small interfering RNA (SiRNA) knockout 
AnxA2 cells showed reduced Cltx binding as well as reduced migration (Kesavan et 
al., 2010). Cltx has a promising therapeutic target to glioma and related solid 
tumours. Although, the mechanism of action of Cltx is very complicated and far from 
clear at both cellular and molecular levels. The mechanism of chlorotoxin action 
needs to be investigated if clinical studies are to progress satisfactorily. The 
relationship of Cltx binding to both MMP2 and AnxA2 is controversial and further 
work is needed to clarify a complex situation. A number of chlorotoxin-like short-
toxins (Cltx-like short toxins) have been isolated from venom of different scorpion 
species (Wudayagiri et al., 2005; Newton et al., 2007; Ali et al., 2016). Chlorotoxin 
homologues might have therapeutic value in glioma and range of cancers.  
In-vitro experiments are costly and time consuming hence in-silico computational 
studies are being considered as a reliable alternative (Coelho et al., 2016; Kumar et 
al., 2015) used to study protein-protein interaction, enzyme inhibitor complex and 
drug design. In-silico computational studies are fast, reliable approach in selecting 
broad range of inhibitor of an enzyme, drug development, drug selectivity (Coelho et 
al., 2016).  
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1.4 Homology modelling 
Determination of 3D structures of protein by X-ray crystallography and NMR 
spectroscopy are slow and time-consuming methods without guaranteed success 
especially for membrane proteins (Floudas et al., 2006). There are many more 
available sequences of proteins in databases than solved crystal structures of 
proteins and there is a constant increase in the generation of the sequences of 
proteins than solved 3D structures (Moult et al., 2014). Homology modelling is a 
reliable and accurate method used to generate 3D models of a protein from its amino 
acid sequence, using an existing crystal structure (template) for an evolutionarily 
related protein (target). The critical assessment of structure assessment (CASP) is 
world-wide study to test protein-prediction methods (Moult et al., 2014). Mainly, 
CASP experiments test and provide help to advance the methods of 3D model 
prediction of proteins via blind prediction (Moult et al., 2014). Homology modelling is 
a reliable procedure for protein prediction assessed by CASP. The Swiss-Model is a 
fully automated homology modelling web-server used to predict 3D structure of a 
protein from its amino acid sequence as PDB format output (Bordoli et al., 2009). 
Recently, Swiss-Model has been used extensively world-wide, predicting 0.9 million 
requests for protein models each year (Biasini et al., 2014). 
 
1.5 Protein-protein docking 
Protein-protein docking is performed to investigate the interaction between two 
proteins or between a drug and a protein (Coelho et al., 2016). Docking is performed 
to analyse binding affinities of a protein on its target molecule which is helpful in 
enzyme-inhibitor interaction, drug design etc. (Kozakov et al., 2013; Coelho et al., 
2016).  
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It is possible to study the interaction of chlorotoxin and related Cltx-like short toxins 
with putative binding targets such as MMP2 and AnxA2 using docking studies. Study 
of their interaction, evaluate binding sites on targets, binding affinities and to select 
toxins that have higher binding affinities. X-ray crystallography is a slow and time-
consuming method. To date only the 3D structures of Cltx and Insectotoxin I5A have 
been determined so far. Homology modelling has provided a fast, robust and reliable 
method to predict 3D models of Cltx-like short toxins from their sequences and then 
to evaluate quality assessment in order to find their usefulness in a subsequent 
docking study (Moult et al., 2014).  
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2 AIMS and OBJECTIVES 
 
2.1 AIMS   
The aims of the project are to study interaction of chlorotoxin and related toxins with 
its proposed putative binding partners MMP2 and annexin A2, using an in-silico 
approach in order to understand the mechanism of action of chlorotoxin. 
 
2.2 OBJECTIVES 
• To study existing 3D models of MMP2, perform quality assessments and then 
to dock chlorotoxin to MMP2 models using the ClusPro docking programme.  
 
•  To study which domains of MMP2 (the catalytic domain, fibronectin module 
type-II domains and the hemopexin domain) are important in binding.  
 
 
• To study annexin A2 3D models, and to assess stereochemistry of models. To 
dock chlorotoxin to annexin A2 models and study their interaction. 
 
• To use molecular modelling to predict 3D models of the chlorotoxin-like short-
toxins and docking techniques to study the mechanism of action of 
chlorotoxin-like short-toxins with a view to the development of new clinical 
agents. 
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3     CHLOROTOXIN DOCKING with MMP2 and ANNEXIN A2 
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3.1 Introduction  
Glioblastoma (GBM) is the most common metastatic primary brain cancer (Lee et al., 
2015). MMP2 proteolytic enzyme is overexpressed in GBM and involved in its 
invasion and metastasis (Deshane et al., 2003). AnxA2 is a calcium-binding 
cytoskeletal protein highly expressed in GBM and involved in angiogenesis 
(Tatenhorst et al., 2006). Both MMP2 and AnxA2 are potential candidates for 
targeted therapy for GBM as discussed in previous chapter. A number of studies are 
under investigation to target MMP2 and AnxA2 thus inhibit GBM metastasis and 
increase survival-rate. 
Chlorotoxin (Cltx) is a 4kD peptide derived from venom of Leiurus quinquestriatus 
scorpion (DeBin et al., 1993). It consists of 36 amino acids and its sequence is 
MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR (DeBin et al., 1993).  It 
has a compact structure which is supported by four disulphide bridges which link all 
cysteine residues present in its sequence. It contains 3 small β-sheets packed 
around an α-helix (Lippens et al., 1995).  
Cltx was originally shown to block small-conductance epithelial chloride channels 
when applied internally (DeBin et al., 1993). Later, studies suggested that Cltx binds 
to MMP2 and facilitates its internalisation, thus reducing MMP2 enzymatic activity on 
the surface (Deshane et al., 2003). To complicate matters further, annexin A2 
(AnxA2) was proposed a potential target for Cltx (Kesavan et al., 2010). However, 
the mechanism of action of Cltx interaction with its proposed targets is far from clear.  
In-silico homology modelling and docking is a reliable method to study molecular 
interactions (Vyas et al., 2012). Protein modelling and docking is a reliable and cost-
effective method which is used to provide information on predicted interactions 
(Moult et al., 2014). This type of in-silico approach is used to find interaction of Cltx 
with its putative targets MMP2 and AnxA2 and shed light on its mechanism of action.  
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This approach has been used before in the study of scorpion toxins. Charybdotoxin 
(ChTx) is a short scorpion venom peptide that blocks voltage-gated potassium 
channels (Froy et al., 1999). The 3D structure of ChTX was experimentally 
determined by NMR spectroscopy (Bontems et al., 1992). Khabiri et al., (2011) used 
in-silico modelling and docking in order to study the interaction of ChTX with the 
potassium channel Kv1.3. Kumar et al., (2015) investigated potential inhibitors of 
ChTX toxin via in-silico study. Recently, Farsani et al., 2015 modelled a Cltx 
homologue (Cltx-like peptide MeICT) and studied its interaction with the catalytic 
domain of MMP2 (1QIB structure) using an in-silico approach. The 3D structure of 
full-length MMP2 is present in mutant form (PDB code: 1CK7). Morgunova et al., 
(1999) introduced a mutation (E404A) in order to prevent the protein from auto-
proteolysis during crystallisation.  
 In order to mimic the in-vivo scenario, 1CK7 structure was un-mutated to form a 
native MMP2 model. To represent Cltx interaction with an activated MMP2, the 
activation peptide of MMP2 was cleaved. Then, interaction of Cltx was studied with 
its putative binding partners, MMP2 and AnxA2.  
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3.2 Methodology.  
3.2.1 3D protein structures and visualisation by RASMOL and Swiss Deep-
View. 
 
The amino acid sequences of Cltx, MMP2 and AnxA2 were extracted from the 
UniProt database (http://www.uniprot.org/). The 3D structures of Cltx (1CHL) and 
annexin A2 (2HYW) were obtained from RCSB PDB-databank (www.rcsb.org/) in 
PDB format. Various 3D structures of MMP2 and its individual domains were also 
downloaded from RCSB-PDB databank (www.rcsb.org/), full-length MMP2 (1CK7, 
Morgunova et al., 1999), the catalytic domain of MMP2 (1QIB, Dhanaraj et al., 1999), 
first Fib-II domain (1KS0, Gehrmann et al., 2002), second Fib-II domain (1CXW, 
Briknarova et al., 1999), third Fib-II domain (1J7M, Briknarova et al., 2001) and the 
C-terminal domain of MMP2 (1RTG, Gohlke et al., 1996). The 3D structure of 
charybdotoxin (2CRD) was downloaded in a PDB format from PDB-databank.  
RASMOL and Swiss Deep-View software, developed by Swiss Institute of 
Bioinformatics (SIB), were used to visualise and analyse one or several protein 
models or structures at same time (Ramadan et al., 2014; SIB ExPASY, 2016). 
Swiss Deep-View can analyse, manipulate as well as superimpose proteins to 
visualise different aspects of a protein. Swiss Deep-View superimposes proteins by 
using root mean square deviation (RMSD) algorithm by measuring the average 
distance between the atoms of superimposed molecules (ExPASY, 2016). Swiss 
Deep-View was used to superimpose 3D structures of various regions of MMP2 on 
full-length MMP2 using the ‘magic fit’ tool. Then, all models were highlighted in 
different colours using the ‘colour layer’ tool. Charged surfaces of a 3D model or 
structure can also be determined by Swiss Deep-View (Ramadan et al., 2014). The 
electrostatic surfaces of Cltx and MMP2 were calculated using Swiss Deep-View 
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programme using the Poisson-Boltzmann method. The default software parameters 
were used to calculate charged surfaces.  Calculated positively charged surfaces are 
coloured in blue (1.8 kT/e), negatively charged are in red (-1.8 kT/e), and neutral 
regions (no charge) are coloured in white, where ‘k’ is the Boltzmann constant, ‘T’ is 
the temperature in Kelvin, and ‘e’ is the charge of the electron.   
 
3.2.2 Homology Modelling  
Swiss Institute of Bioinformatics (SIB) Swiss-Model (https://swissmodel.expasy.org/) 
uses automated comparative modelling to predict 3D models of a protein from its 
amino acid sequence using an existing crystal structure ‘template’ for an 
evolutionarily related protein ‘target’. Three isoforms of MMP2 (1CK7) structure were 
predicted and downloaded in PDB format. In order to predict the native 3D structure 
of MMP2, the Ala404 mutation was deleted and Glu amino acid was inserted in its 
place. Then, the sequence was uploaded to Swiss-Model to predict the native 3D 
model using automated comparative modelling. Native MMP2 structure (1CK7‒) was 
predicted based on MMP2 template (PDB code: 1CK7) and MMP2 in conjunction 
with TIMP2 (PDB code: 1GXD) template in PDB format. In order to predict the 3D 
model of activated MMP2, the activation peptide (30-109 amino acids) of MMP2 
(1CK7) was cleaved by Signal P server. Sequence was then uploaded to Swiss-
Model to predict 3D model of activated MMP2 (1CK7 A‒). To predict native activated 
MMP2, the activation peptide was cleaved, the Ala404 mutation was deleted and Glu 
amino acid was inserted in its place and then (1CK7‒A‒) was predicted.  
 
3.2.3 Quality assessment 
It is very important to estimate the quality of the 3D models as they may contain 
geometrical errors such as disorientated side chains. Qualitative Model Energy 
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ANalysis (QMEAN) is an estimate of the quality of a 3D model using several 
geometrical aspects and a comparison to experimental structures of similar sizes 
(Benkert et al., 2011). The Z-Score compares the QMEAN6 score to scores of a set 
of non-redundant high-resolution 3D structures of similar size experimentally 
determined by X-ray crystallography (Korneta et al., 2012).   
 Models were subjected for quality checks using Swiss-Model workspace 
(http://swissmodel.expasy.org/workspace/). QMEAN6 and Z-Score measures 
absolute quality and studies structural geometrical features of a 3D model compared 
to experimentally determined 3D structure of similar size (Korneta et al., 2012). 
QMEAN uses a reliability score ranging between 0 to 1; a value of a model closer to 
1 represents a better quality model and indicates ‘the degree of near-nativeness’ of a 
predicted model (Benkert et al., 2011).   
The QMEAN6 consists of a combination of 6 structural descriptors using statistical 
potentials used for quality estimation of a 3D model (Benkert et al., 2011). A torsion 
angle potential over three consecutive residues examines the back-bone local 
geometry of a 3D model. Long-range interactions of the 3D model are evaluated by 
two distant-dependent interactions potentials called Cβ interaction and all-atom 
interaction. The residue level interactions are assessed based on C-β atoms only, 
while all-atom interactions are used to assess long range interactions. The solvation 
potential identifies burial status of amino acids. In addition, QMEAN6 uses 2 extra 
statistical terms which describe the agreement between predicted (from sequence) 
and calculated secondary structure as well as solvent accessibility. DFIRE (distance-
scaled, finite ideal-gas reference state) is an all atom potential energy function of a 
protein 3D structure (Zhou et al., 2002). Lower the DFIRE energy values means best 
quality protein models (Mishra and Hoque, 2015). 
Procheck Ramachandran plot evaluates the stereochemistry of a predicted 3D model 
(Laskowski et al., 1993). Ramachadran plot investigates the backbone dihedral 
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angles ψ and φ of the residues of the 3D model and compare it to the stereo-
chemical values of the experimentally derived 3D structures (Krishnamoorthy et al., 
2016).  
 
3.2.4 Protein-protein docking 
ClusPro is a rigid-body docking programme used to evaluate protein-protein 
interactions (Kozakov et al., 2013). The ClusPro docking programme 
(www.cluspro.bu.edu) was used to dock Cltx with its putative binders MMP2 and 
AnxA2. ClusPro covers translational and rotational space of relative positions 
between peptide and protein and generates thousands of docked complexes. It 
represents the receptor molecule on a fixed grid and the ligand on a movable grid 
and rotates the ligand in a rotational and translation confirmation relative to the 
receptor. It generates 1000 complexes, clusters them and then minimises them via 
CHARMM (Chemistry at HARvard Macromolecular Mechanics) molecular simulation 
programme to find near-native complexes (Kozakov et al., 2013). Cluspro identifies 
near-native complexes by assuming that a near-native structure will have the largest 
cluster together with the lowest energy (stable clusters) (Xia et al., 2016). The 
number of docked structures within the top cluster above 122 members indicate a 
well-defined set of encounter complexes and provides assurance that the clustering 
of docked structures occurs in the neighbourhood of the native state. The lowest 
energy of the top cluster represents stability of the cluster and further increases 
confidence in its near-nativeness (Kozakov et al., 2017).  
MMP2 isoforms and AnxA2 were selected as 'receptor' and Cltx was selected as a 
'ligand' and then submitted to ClusPro server under default software parameters. As 
a control, charybdotoxin (ChTX) was selected as ‘ligand’ and then docked to the 
native activated MMP2. 
Page 35 of 125 
The top cluster (with largest number of members) was downloaded in PDB format 
and then visualised in PyMOL. PyMOL software (www.pymol.org/) is a molecular 
visualisation system developed by Schrödinger Inc. Ligand and receptor were 
highlighted in separate colours to facilitate visualisation of protein complexes. 
Residues of ligand and receptor were visualised at 20 angstroms and residues of 
interest were coloured. Docked pockets were predicted by selecting ‘surface’ for 
receptor and ‘stick’ display for ligand.  
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3.3 RESULTS 
3.3.1 Quality assessment of the MMP2 models.  
The 3D structures of MMP2 (1CK7), Cltx (1CHL) and AnxA2 (2HYW) were 
downloaded from the RCSB-PDB databank; the 3D models of MMP2 isoforms were 
predicted utilising Swiss-Model. 
The quality of 3D models of MMP2 was assessed using Swiss-Model workspace to 
find their usefulness in docking studies. Firstly, the quality of the 3D structure of 
MMP2 (1CK7) was assessed by QMEAN6, Z-Score and Ramachandran plot 
statistics (Fig 3.1). The QMEAN6 score for MMP2 structure (0.68) was within the 
acceptable range (The QMEAN6 score range from 0 to 1 with higher score for more 
reliable models). The Z-Score of MMP2 represented by a red star (Fig 3.1b) is within 
the Z-Scores of the reference 3D structures located in PDB-databank. The Z-Score 
for MMP2 was -0.92 which means the MMP2 3D structure is of comparable quality to 
high-resolution experimental structures of similar sizes (structure size +/- 10%) 
located in the PDB-databank. The Ramachandran plot (Fig 3.1c) shows that 88% 
residues of 1CK7 exhibit dihedral (φ and ψ) values in core region, 11.7 % allowed, 
0% generously allowed and 0% in the disallowed region. 
The quality of the other 3 isoforms of MMP2 was then assessed and compared to 
parent 1CK7 (see appendix for QMEAN6, Z-Score, DFIRE and Ramachandran plot). 
Overall, all models have good quality; QMEAN6 and Z-Score for all models are within 
an acceptable range (Table 4.1.0). All models had low energy values hence low 
steric hindrance and no clashes in atoms which means that the models have good 
stability (table 3.2). None of residues were in the disallowed region for all other 
isoforms of MMP2. Both 1CK7 and 1CK7-A- showed a similarity in Z-Score values 
that of -0.923 and -0.974 respectively. QMEAN6 values for all three models are in a 
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similar range (Table 3.2). In general, the quality data of all models falls within an 
acceptable range, showing a high similarity to parent 1CK7 (Table 4.1.0).  
 
 
Fig 3.1. Stereochemistry and quality assessment of MMP2 models. (a) QMEAN6 score 
of full-length MMP2 (1CK7, E404A mutant with activation peptide), and identification of the 
score of individual geometrical features (b) QMEAN Z-Score of 1CK7, different shades of 
grey and black colour represent Z-Scores of the reference structures located in PDB-
databank and red star represents MMP2 (c) shows Ramachandran plot statistics of 1CK7 3D 
structure. Red coloured region of Ramachandran plot shows residues in the most 
favoured region and yellow region show residues in the allowed region, grey region 
shows residues in generously allowed region and white region shows residues in the 
disallowed region. Glycine can be located in white regions as it does not contain a 
side chain. 
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Table 3.2. The quality assessment of 3D models of MMP2 isoforms. QMEAN6 and Z-
Score values of all 4 models are within an acceptable QMEAN range. All models have a low 
energy hence less steric clashes. All models are good structures and comparable to a set of 
experimentally determined 3D structures of similar sizes from PDB databank.  
 
The quality data suggested that the MMP2 3D structure as well as 3D models of 
MMP2 isoforms had an overall good quality and could be used in docking studies. 
Models DFIRE energy QMEAN6 (Z-Score) Residues in disallowed  
region % (Ramachandran) 
1CK7 -886.77 0.68 (-0.923) 0  
1CK7‒  -868.60 0.717 (-0.512) 0 
1CK7 A‒ -749.73 0.69 (-0.815) 0 
1CK7‒ A‒ -768.63 0.676 (-0.974) 0 
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3.3.2 Charged surfaces of MMP2 models and effect of the point mutation. 
The electrostatic surface potential of different MMP2 models was predicted by Swiss 
Deep-View and the effects of a point mutation on charged surfaces were studied. 
Charged surfaces of full length recombinant MMP2 (1CK7), native MMP2 with an 
activation peptide and without mutation (1CK7-), recombinant MMP2 with mutation of 
E404A and without activation peptide (1CK7 A-) and MMP2 without activation 
peptide and point mutation (1CK7- A-) were calculated (Fig 3.3).  
The electrostatic charged surfaces reveal that all four models of MMP2 have an 
overall negative charge (Fig 3.3). The full-length MMP2 (1CK7) and native MMP2 
contain a neutral charged region as well as a positively charged region at the 
activation peptide (Fig 3.3a and b). MMP2 models without the activation peptide 
have a highly negatively charged region around the catalytic domain. Both MMP2 
models 1CK7 and 1CK7‒ show a similar charge distribution around their surfaces. 
There are no differences in overall charged surfaces between these two models (Fig 
3.3a and b). The addition of Glu at position 404 in the catalytic domain did not affect 
charged surfaces of native MMP2 model (1CK7‒). Both models have an overall 
negatively charged region around the catalytic and fibronectin domains. The C-
terminal domain has neutral and positive regions particularly around blade 3 and 4. 
However, the activation peptide has neutral (no charge) as well as positive surfaces 
near the helix regions. Figures 3.3c show a highly negatively charged surface is 
exposed by removal of activation peptide near catalytic domain, this region is highly 
negative in both 1CK7 A‒ and 1CK7 ‒ A‒ isoforms. The point mutation does not affect 
charged surfaces of MMP2, however removal of the activation peptide shows a 
highly negatively charged region (Fig 3.3), although there is a slight difference in the 
orientation between these two models. 
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Figure 3.3. Charged surfaces of MMP2 isoforms. (a) Charged surfaces of 1CK7, (b) 
Native MMP2 1CK7-, (c) 1CK7 A-, (d) native activated MMP2 1CK7- A-. Different colour 
codes are red (-1.8 kT/e) and blue (1.8 kT/e) where ‘k’ is the Boltzmann constant, ‘T’ is the 
temperature in Kelvin, and ‘e’ is the charge of the electron. Default charge parameters of the 
programme were selected for calculation of charged surfaces of different isoforms of protein 
models.  
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3.3.3 Superimposition of 3D structures of MMP2, structure similarities and 
differences. 
 
The MMP2 3D model was superimposed on the 3D structures of various regions of 
MMP2 to identify similarities and differences between different structures. The MMP2 
3D structure was superimposed on the catalytic domain of MMP2 (1QIB), the first 
Fib-II domain of MMP2 (1KS0), the second Fib-II domain (1CXW), the third Fib-II 
domain (1J7M) and the C-terminal domain of MMP2 (1RTG). The catalytic domain of 
MMP2 (1QIB) show high structural similarity to the standard domains of 1CK7 A-. 
Both 1CK7 A- and 1QIB structures have β-sheets and 3-α helices which 
superimpose perfectly (Fig 3.4). However, there is small difference between the 
connective loops at N-terminal and C-terminal region which is highlighted with red 
arrows. The Fib-II domains are superimposed on Fib-II domains of 1CK7 A-. Figure 
3.4 shows that β-sheets of all three Fib-II domains superimpose well on 1CK7 A- with 
a small difference in loop alignment at the N-terminal and the C-terminal domains of 
Fib-II domains, which is highlighted with green arrows. Differences in loops are 
present due to the fact that each individual Fib-II domain is superimposed on full-
length 1CK7 A-.  
The C-terminal domain of MMP2 (1RTG) is superimposed on the MMP2 model as 
shown in Fig 3.4. Both structures contain four disc-shaped propellers and equal 
number of superimposed β-sheets. However, disc III of 1RTG has a β-sheet that is 
slightly longer than full-length MMP2 C-terminal domain, which is highlighted by a 
brown arrow (Fig 3.4). In general, all different models of MMP2 have similar 
structures to 1CK7 and there is only a small difference, particularly in loop regions 
between the structure of full-length MMP2 and its various published domains. Either 
full-length MMP2 or MMP2 model without its activation peptide can be used in 
docking studies rather than using each individual model, as it may represent a 
reliable interaction and an in-vivo scenario. Tao et al., (2009) cleaved the activation 
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peptide and used activated MMP2 in a protein docking study, in the present study it 
was decided to use either full-length MMP2 or an activated MMP2 model. 
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Fig 3.4. Superimposition of MMP2 1CK7 A- on different structures of MMP2 by Swiss 
Deep-View. The full-length MMP2 without activation peptide (1CK7 A-) is coloured yellow, 
the catalytic domain only (1QIB) is coloured in blue, 1st Fib-II (1KS0) is coloured in red, 2nd 
Fib-II domain (1CXW) is coloured in grey, 3rd Fib-II (1J7M) domain is coloured in pink and C-
terminal domain (1RTG) is coloured in green. Red arrows highlight differences in structures 
of 1CK7 A- and 1QIB, green arrows highlight differences in structures of the Fib-II domains 
while brown arrows represent differences in 1CK7 A- and C-terminal domain (1RTG). A 
brown arrow in the show different sizes of a β-sheet of the C-terminal domain. 
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3.3.4 Chlorotoxin docking to MMP2 
MMP2 is a proposed target for Cltx however the mechanism of action is unknown 
hence Cltx was docked to full-length MMP2 to assess its feasibility as a binding 
partner. ClusPro generated a top cluster of Cltx-MMP2 complexes and this top 
cluster contained the highest number of docked structures. Top clusters and their 
energy scoring function were obtained in order to analyse accurate predictions of 
binding affinity of the peptide-protein complexes. The top cluster showing Cltx 
interaction with full-length MMP2 (1CK7) was further examined. Cltx is bound to the 
catalytic domain and second Fib-II domain in the top cluster structure (Fig 3.5.1a). 
The N-terminal region of Cltx is docked to the 2nd Fib-II domain and β-sheets are 
docked near the catalytic domain of MMP2 (Fig 3.5.1a). Similarly, Cltx is also docked 
to native MMP2 (1CK7-) near the catalytic and the 2nd Fib-II domain (Fig 3.5.1b) and 
a similar face of Cltx is interacting with both recombinant and native MMP2 targets. 
This interaction provides evidence that E404A does not affect binding locus of Cltx 
on full-length MMP2. However, both MMP2 models contain an activation peptide at 
N-terminal domain, which is cleaved during in-vivo activation of MMP2 (Springman et 
al., 1990).  
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Figure 3.5.1. The top clusters of Cltx docked to human MMP2 via ClusPro. Cltx is 
highlighted in red circle, α-helix of Cltx is shown in red colour while β-sheets are shown in 
yellow colour. The α-helices of MMP2 are coloured in cyan and β-sheets are coloured in 
magenta. (a) Cltx is docked to full-length MMP2 (1CK7) at the catalytic and Fib-II domain of 
MMP2. (b) Cltx is docked to full-length MMP2 without point mutation (1CK7-) in a similar 
position.  
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The binding pockets of the docked complex was determined by PyMOL. The top 
docked clusters of Cltx-1CK7 and Cltx-1CK7- were analysed in order to find the 
binding locus of Cltx on MMP2. The top cluster shows that Cltx is docked in a pocket 
of MMP2, especially between the catalytic and the 2nd Fib-II domain. The N-terminal 
region of Cltx is present in close contact with the 2nd Fib-II domain whereas the C-
terminal domain is in close contact with the catalytic domain of MMP2 (Fig 3.5.2).  
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Figure 3.5.2. Cltx docked to MMP2. MMP2 is shown as grey surface and Cltx is shown in 
cyan. (a) Cltx is bound in a pocket between the catalytic domain and the Fib-II domain of 
MMP2 (1CK7). (b) Cltx is docked to 1CK7- particularly bound in a pocket between the 
catalytic domain and second Fib-II domain.  
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3.3.5 Chlorotoxin docking with MMP2 without activation peptide. 
Cltx was docked to recombinant MMP2 without the activation peptide (1CK7 A-). The 
top cluster shows that Cltx interacts with 1CK7 A- and is docked at the catalytic 
domain of MMP2 (Fig 3.5.3a). Cltx was then docked to native MMP2 without the 
activation peptide (activated MMP2, 1CK7- A-) as this would represent an in-vivo 
interaction. A similar docking pose is observed in the top cluster of Cltx and 1CK7- A- 
complex (Fig 3.5.3b). The top cluster shows that Cltx is bound near α-helices of the 
catalytic domain of 1CK7- A-. In both clusters, Cltx is docked to MMP2 without 
activation peptide differently than MMP2 with an activation peptide (Fig 3.5.3).   
 
 
Figure 3.5.3. Cltx is docked to MMP2 without activation peptide. Cltx is highlighted in 
red circle, α-helix of Cltx is coloured in red and β-sheets are coloured in yellow. The α-
helices of MMP2 are coloured in cyan and β-sheets are coloured in magenta. (a) Cltx is 
docked at the catalytic domain of recombinant MMP2 (E404A) without an activation peptide 
(1CK7 A-), (b) shows Cltx docked to native MMP2 without activation peptide (that is Glu404, 
1CK7- A-).  
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Subsequently, the top clusters of Cltx and MMP2 without activation peptide were 
analysed by PyMOL programme. Cltx is docked in deep pockets of MMP2 target at 
the catalytic domain which represents interaction between Cltx and its target protein 
(Fig3.5.4). Cltx is interacting with both the mutated and native variant as  shown in 
figure below. 
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Figure 3.5.4 Cltx docked to MMP2 without activation peptide. Grey surface represents 
MMP2 target and Cltx is shown in cyan colour (a) Cltx is docked at the catalytic domain of 
MMP2. Amino acids of Cltx that are in close contact with target are labelled. (b) Cltx is 
docked at the catalytic domain of MMP2 without activation peptide and without mutation. 
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The MMP2 model without activation peptide and point mutation represents in-vivo 
activated enzyme, the top docked cluster of Cltx and 1CK7-A- may provide an in-
silico model for the in-vivo interaction. The interaction of Cltx/1CK7-A- was therefore 
analysed at the residue level by using PyMOL programme. Cltx is bound in deep 
pockets of the MMP2 catalytic domain as shown in Fig 3.5.5. Analysis of the top 
cluster shows that amino acids located at the C-terminal domain of Cltx are 
particularly positive residues such as Arg25 and Arg36 present in close contact to 
MMP2 (Fig 3.5.5). Amino acid Lys23 of Cltx is present in close contact with Asp77 
and Asp80 of MMP2 and Arg25 and Arg26 positive residues of Cltx are present in 
close contact of Glu296 and Glu304 respectively which represent electrostatic 
interactions between two proteins. Another positive residue Lys27 of Cltx is also 
penetrated deeply in the catalytic domain of MMP2.  An aromatic residue Tyr29 of 
Cltx is present in proximity of Thr318 of MMP2. However, Arg14 and Lys15 are 
present in free space and are not involved in interaction with target MMP2 (Fig 
3.5.5).  
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Figure 3.5.5. Interaction of Cltx and activated MMP2 (1CK7-A-) in the top docked 
cluster. Cltx ligand is coloured in cyan and target MMP2 is coloured in green. Amino acids 
of MMP2 that are contacting with Cltx are coloured red. Amino acids of interests on both Cltx 
and MMP2 are labelled. Mostly, positive residues of Cltx at C-terminal domain of the peptide 
are present in close contact to negative amino acids of MMP2.  
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3.3.6 Energy Scoring of docked complexes of Cltx-MMP2. 
Energy scoring provides information on stability and binding affinity of docked 
complexes of peptide and target proteins. The most likely, near-native confirmation is 
determined by the largest cluster size (that is the highest number of docked 
neighbour structures in a cluster) and lowest energy (Kozakov et al., 2013). Lowest 
energy regions tend to predict bigger clusters of docked complexes. Differences in 
binding energy values of docked complexes represent differences in binding affinity. 
According to table 3.6, the top cluster of Cltx and native activated MMP2 (Cltx/1CK7-
A-) is a large cluster with strong binding affinity. This complex has the highest 
number of docked structures within the cluster and include 183 members. This 
complex also has the lowest energy of -956.5 which represent strong binding 
between two proteins. The centre docked structure of Cltx/1CK7-A-  in the top cluster 
has energy of -709.5 which represents the stability of the cluster and a stronger 
binding affinity than other docked clusters (table 3.6). The top cluster of Cltx docked 
with mutant MMP2 without the activation peptide (Cltx/1CK7 A-) ranked second on 
the list. The Cltx/1CK7 A- cluster contains 179 members and a docked structure 
within cluster has -890 lowest energy. This suggests a strong binding affinity of Cltx 
with 1CK7 A-, however target MMP2 has a mutation. Hence, Cltx/1CK7-A- large 
cluster together with lowest-energy indicates that the proposed docking complex is 
likely to reflect the position of near-native binding.  
 
 
 
 
 
 
Page 54 of 125 
 
 
Peptide/Protein 
 Complex 
Cluster Members Representative Weighted Score 
Cltx/1CK7 1 135 Centre -729.5 
Lowest energy -829 
Cltx/1CK7- 1 153 Centre -766 
Lowest energy -778 
Cltx/1CK7 A- 1 179 Centre -890 
Lowest energy -890 
Cltx/1CK7-A- 1 183 Centre -709.5 
Lowest energy -956.5 
 
Table 3.6 Energy score profile of Cltx-MMP2 docked clusters. Members represents size 
of the docked complexes, that is number of docked structures within a cluster. Energy of 
cluster centre represents energy of docked complex that has the highest number of member 
or neighbours in the cluster and energy of the docked complex in cluster with lowest energy.  
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3.3.7 Charybdotoxin docking with MMP2. 
Charybdotoxin (ChTX) is a calcium-activated potassium channel toxin isolated from 
Leiurus quinquestriatus scorpion venom (Laurent et al., 1993). The 3D structure of 
ChTX was downloaded in PDB format from PDB-databank (PDB code: 2CRD) and 
then docked to the native activated MMP2 for negative control. The top cluster show 
that ChTX is docked near the first Fib-II domain and the second Fib-II domain (Fig 
3.7). The ChTX is bound very differently to MMP2 compared to that of Cltx. The 
energy score shows a very binding affinity between ChTX and MMP2. The top 
cluster contains a structure with lowest energy of -512.5 hence very weak binding 
compared to that of Cltx binding to MMP2. This indicates that ChTX does not bind to 
MMP2 and therefore data of the present study with Cltx is validated, as one would 
expect based on experimental studies that Cltx interacts with MMP2 (Deshane et al., 
2003; Alam et al., 2012; Xu et al., 2016). 
 
 
Figure 3.7. Top docked cluster of ChTX and MMP2. The ChTX is highlighted in red circle 
which is docked to the Fib-II domains of MMP2. The β-sheets of MMP2 are coloured in 
magenta and alpha-helices are coloured in cyan.  
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3.3.8 Cltx docking with Annexin A2 
3.3.8.1. Cltx docking with human Annexin A2 with calcium bound  
AnxA2 has been proposed a putative target for Cltx as the activity of AnxA2 was 
inhibited by Cltx in glioma studies (Kesavan et al., 2010). Cltx was docked to human 
AnxA2 in order to study their binding interaction. The 3D structure of AnxA2 (PDB 
code: 2HYW, chain A) was determined by X-ray diffraction studies at 2.10Å by Shao 
et al., (2006). 2HYW contains 4 structurally similar homologous repeats of 5 α-
helices (I-IV) arranged in a near-parallel shape, starting from Asn31 to Asp338 making 
a curved disk shape structure (Shao et al., 2006). 2HYW shares structural similarity 
to human AnxA2 (PDB code: 1XJL), both 2HYW and 1XJL contain 7 Ca2+ ligands.  
Analysis of the top cluster show Cltx docked to repeat-I and IV of AnxA2 (Fig 3.8). 
The N-terminal domain of Cltx as well as β-sheets in the C-terminal domain are 
interacting with AnxA2 whereas α-helix of Cltx does not interact with the protein.  
 
 
Figure 3.8. The top docked cluster of Cltx and AnxA2. (a) α-helices of AnxA2 are 
coloured in cyan and 4 homologous repeats that consists of α-helices are labelled. Cltx is 
highlighted in red circle, α-helix of Cltx is shown in red colour while β-sheets are coloured in 
yellow. (b) Cltx (cyan) docked in AnxA2 pockets (wheat).  
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The energy profile show that Cltx has binding affinity to AnxA2. The top cluster has 
large size and there are 288 docked members present in cluster 1 (table 3.9). The 
structure with strong binding affinity has lowest energy of -659.5 and a structure 
within cluster has centre energy of -561 (table 3.8). Although, Cltx-AnxA2 has highest 
number of members docked at similar locus on AnxA2 and there is stable binding 
between Cltx and AnxA2. However, binding affinity is weaker as compared to that of 
Cltx-MMP2 cluster (table 3.9).   
 
Peptide/Protein 
 Complex 
Cluster Members Representative Weighted Score 
Cltx-AnxA2 1 288 Centre energy -561 
Lowest energy -659.5 
 
Table 3.9. Energy score profile of Cltx-AnxA2 cluster. The top cluster contains 288 
docked members i.e. docked structure at similar locus in the top cluster. Strong binding 
affinity of a structure within top cluster is represented by lowest energy. In addition, a docked 
structure at centre of the cluster also has good binding affinity with energy of -561.  
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3.4 Discussion. 
MMP2 and AnxA2 are over expressed in GBM hence targeting these proteins is 
crucial for GBM treatment (Lokman et al., 2011). Cltx was docked to its proposed 
putative targets MMP2 and AnxA2 in order to study their interaction. All 3D structures 
of MMP2 superimpose and there is no big difference between the models, hence 
Cltx docking to individual MMP2 regions is unnecessary. Thus, Cltx was docked to 
native MMP2 as well as activated MMP2 in the present study. 
The results in the present study suggest that Cltx interacts with MMP2. This 
correlates with Deshane et al., (2003) who showed that Cltx interacted with MMP2 
and reduced its enzymatic activity via matrigel invasion assay and an enzyme-linked 
immunosorbent binding assay as well as gelatin zymography. Alam et al., (2012) and 
Ali et al., (2016) showed that Cltx inhibited the activity of MMP2 via FRET substrate 
assay and gelatin zymography. 
The results show that Cltx is docked to full-length MMP2 between the catalytic 
domain and the Fib-II in the top cluster. Docking Cltx to the catalytic domain only 
(1QIB) or any other individual 3D structure of a region of MMP2 is not justified as it 
may not represent an in-vivo scenario.  
Tao et al., (2009) cleaved the activation peptide of MMP2 in order to access the 
catalytic site to mimic the in-vivo scenario and then docked it to SB-3CT inhibitor. In 
our study, the activation peptide was cleaved and then MMP2 1CK7 protein was un-
mutated in order to study Cltx interaction with native MMP2. Removal of the 
activation peptide exposes a site that was covered by the activation peptide in full-
length MMP2. Results indicated that Cltx has a stronger binding affinity with native 
activated MMP2 than the other forms of MMP2 tested. Farsani et al., (2015) 
conducted an in-silico experiment and docked Cltx-like peptide MeICT (a Cltx 
homologue) with the catalytic domain of MMP2 (1QIB). Although, docking with the 
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catalytic domain only is not justified as 1QIB does not represent a full in-vivo 
activated MMP2. They showed that the α-helix of Cltx-like peptide MeICT docked to 
MMP2 catalytic domain near the α-helices. Our results show that the β-sheets and 
loops of Cltx are docked to MMP2 and α-helix does not seem to be interacting with 
MMP2.  
The present study shows that Cltx has strong binding affinity for activated MMP2 as 
shown in Fig3.5.3. Electrostatic surface analysis showed that MMP2 has a strong 
negatively charged surface as shown in Fig 3.3. Positive residues that are located 
mainly at the C-terminal domain of toxins are present in close contact with MMP2 
(Fig3.5.5). The present study shows that the positive residues such as Arg14 and 
Lys15 do not interact with MMP2 in top cluster and both residues are present in free 
space. This suggests that both Arg14 and Lys15 may be involved in binding to the 
chloride channel and may induce a conformational change to the channel. It is 
possible that Cltx may bind to two separate targets at same time such as MMP2 and 
AnxA2 or chloride channel. Results show that positive residues such as Arg25, 
Lys27 and Arg36 are present in close contact with MMP2 but Arg14 and Lys15 
amino acids are free, Arg14 and Lys15 may interact with other targets of Cltx that are 
AnxA2 or chloride channel (Fig4.2.5).  
AnxA2 is involved in glioma metastasis and angiogenesis and proposed a target for 
Cltx (Kesavan et al., 2010; Zhai et al., 2011). Tatenhorst et al., (2006) and Kesavan 
et al., (2010) suggested that Cltx interacts with AnxA2. The present study indicates 
that Cltx binds to AnxA2 and show that Cltx interacts with AnxA2 near annexin 
repeat-I and IV. However, binding affinity between Cltx-AnxA2 is lower than binding 
affinity of Cltx-MMP2 (table 3.6 and 3.9). Sorocenau et al., (1998) suggested that 
Cltx has a lower binding affinity site and a higher affinity site in GBM. Based on our 
results, it can be assumed that Cltx has stronger binding affinity for MMP2 but lower 
binding affinity for AnxA2 (table 3.6 and 3.9).  
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Molecular dynamics would be useful to confirm results although, MD simulations are 
computationally expensive and requires multicore operating system and performed 
at industry level. This in-silico study provided reliable models and docking 
conformations with various binding affinities. Hence, laboratory screens on 
recombinant homologues can be performed based on these results to focus on 
MMP2 and confirm residues of interests. This rigid-body docking programme did not 
consider Cltx and its targets MMP2 and AnxA2 as flexible molecules and there was 
no conformational change upon binding while docking. Although the conformational 
change for enzyme-inhibitor complex is very small and only occurs in the side chains 
of ligands (Kozakov et al., 2007). Cltx is a small peptide so conformational change 
upon peptide-target association is moderate which does not affect the complex 
backbone geometry and binding affinity. In addition to rigid-body docking, flexible 
docking programme are available such as Rosetta Dock and High Ambiguity Driven 
Biomolecular Docking (HADDOCK) which consider two molecules as flexible 
proteins, however, a priori biological and structural information and binding locus is 
required for Rosetta dock. Moreover, HADDOCK requires a priori knowledge of 
interacting residues prior to docking, since there is a limited knowledge about Cltx 
interaction with its putative partners, Rosetta and HADDOCK are not practical to 
analyse interaction studies. However, rigid-body programme uses a global search of 
two interacting molecules, which is useful if there is a limited data of interacting 
molecule is present hence ClusPro is fast and produced good complexes in our 
study (Kozakov et al., 2013).   
Critical assessment of prediction of interactions (CAPRI) is a communitywide 
experiment that monitors progress of docking programmes (Lensink et al., 2016). 
Cluspro web-server has been used in more than 400 publications (Xia et al., 2016). 
Cluspro ranked top one in CAPRI 2016 blind protein docking, placing it the first best 
predictor web-server (Lensink et al., 2016). 
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4   CHLOROTOXIN-LIKE SHORT TOXINS DOCKING with 
MMP2 and ANNEXIN A2 
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4.1 Introduction 
Although a few studies have attempted to understand the mechanism of action of 
Cltx, there is very limited data available about the structure-functional relationship. 
Attempts have been made to study new Cltx homologues to investigate their 
therapeutic potential (Rjeibi et al., 2010; Farsani et al., 2015; Xu et al., 2016). A 
number of chlorotoxin-like short toxins have been isolated from the venom of 
different scorpion species. Chlorotoxin-like short toxins (Cltx-like short toxins) share 
sequence similarity to Cltx and they may have same therapeutic potential as Cltx (Xu 
et al., 2016). Cltx-like short toxins affecting chloride channels are constrained by 4 
disulphide bridges and they have a consensus formula of CX2CX10CX2CCX5-7CX3-
4CXCXn. Toxins have been isolated (purified) as mature peptide from venom of 
scorpions as well as identified from cDNA libraries using venom gland mRNA. 
Around 34 Cltx-like short toxins have been described, however, only a few toxins 
have been used in experimental studies involving glioma cells. The BMK CT isolated 
from Chinese scorpion Buthus martensii Karsch and Chlorotoxin-like peptide 
(AaCTx) from Androctonus australis share 68% and 61% sequence identity to Cltx 
respectively (Zhao et al., 2010; Rjeibi et al., 2010). Sequence similarity between Cltx 
and these toxins suggests that these toxins have similar functions and molecular 
targets. Both Cltx-like peptide AaCTX and BMK CT inhibited glioma proliferation and 
metastasis in a dose-dependent manner with no effect on normal glial cells (Zhao et 
al., 2011; Rjeibi et al., 2010). Activity of Cltx-like peptide AaCTX was less than 10% 
compared to Cltx in glioma (Rjeibi et al., 2010). It suggests that some toxins may 
have higher efficacy than others. 
Recently, two scorpion toxin derivatives CA4 and CTX23 were designed based on 
Cltx and BMK CT sequences and tested on glioma (Xu et al., 2016). Both CA4 and 
CTX23 decreased glioma cell growth and proliferation. As expected, CA4 and 
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CTX23 did not show cytotoxic effects to normal neurons and astrocytes. CA4 and 
Cltx also inhibited proliferation of endothelial cells demonstrating that both CA4 and 
CTX23 have anti-glioma properties as well as anti-angiogenic properties (Xu et al., 
2016).  
There are many other peptides known as Lqh8/6, chlorotoxoin-1, Insectotoxin I5A 
and GaTx1 that share sequence homology to Cltx (Fig 1). To date, only structures of 
the Cltx and Insectotoxin I5A have been determined (Lippens et al., 1995; Arseniev 
et al., 1993). In this chapter, we will use molecular modelling to predict 3D models of 
the Cltx-like short toxins that have already been used in glioma studies and docking 
techniques to study the mechanism of action of Cltx-like short toxins with a view to 
the development of new clinical agents. Biological functions of CTX23, CA4 and Cltx-
like peptide AaCTX is known as they have been investigated in anti-glioma studies. 
Although, mechanism of action of these toxins is unclear. CA4, CTX23 and Cltx-like 
peptide AaCTX have been used in glioma studies, we decided to study structural-
functional relationship of Cltx, CA4, CTX23 and Cltx-like peptide AaCTX. 
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4.2 Methodology 
4.2.1 Primary Structure of Cltx-like short toxins 
The amino acid sequences of Cltx-like short toxins based on the consensus formula 
CX2CX10CX2CCX5-7CX3-4CXCXn were extracted from bioinformatics database UniProt 
server (http://www.uniprot.org/), and primary literature using Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/). Sequences that contained signal peptide 
were submitted to Signal P 4.1 server (http://www.cbs.dtu.dk/services/SignalP/). Signal 
P cleaves signal sequence of a protein using hydrophobicity scores as signal 
sequence are very hydrophobic in nature (Petersen et al., 2011) and then sequences 
were aligned using Clustal Omega server (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Clustal Omega uses seeded guide trees and Hidden Markov Model (HMM) profile 
method to align multiple sequences (Li et al., 2015). Amino acids were colour coded 
based on their properties using CINEMA colour coding scheme. Negative and positive 
amino acids were coloured in red and blue respectively. Polar amino acids were 
coloured in green and non-polar amino acids were coloured in grey. Highly conserved 
cysteine residues were coloured in yellow. 
  
4.2.2 Secondary structure 
Secondary structure of all toxins was predicted using PSIPRED server 
(http://bioinf.cs.ucl.ac.uk/psipred/). PSIPRED uses a secondary structure prediction 
method to analyse secondary structure of a protein from its primary sequence (Jiang 
et al., 2016). Molecular weight and Isoelectric points of all short-toxins were calculated 
using ExPASY compute pI/Mw tool (http://web.expasy.org/compute_pi/). 
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4.2.3 Generation of 3D models of Cltx-like short toxins and their analysis 
Swiss-Model was used to generate 3D models of CA4 peptide, CTX23 and Cltx-like 
peptide AaCTX via automated comparative homology modelling 
(https://swissmodel.expasy.org/). 3D structures of Cltx (PDB code: 1CHL) and I5A 
(PDB code: 1SIS) present in RCSB PDB databank 
(http://www.rcsb.org/PDB/home/home.do) were used as templates for predicted 3D 
models. Both CA4 and CTX23 were predicted based on 1CHL template whereas, Cltx-
like peptide was predicted based on I5A template. Then, 3D models were subjected 
for quality assessment. The quality of all models was assessed using QMEAN6, Z-
Score, DFIRE energy and Procheck Ramachandran plot via Swiss-Model workspace 
(http://swissmodel.expasy.org/workspace/) as described previously.  
RASMOL and Swiss Deep-View v4.1 was used to visualise and analyse 3D models of 
toxin peptides. Swiss Deep-View was used to superimpose all 3 toxin models and Cltx 
using ‘magic fit’ tool. The electrostatic surfaces of the 3D models and Cltx was 
calculated using Swiss Deep-View as described previously in 3.2.  
4.2.4 Docking of Cltx-like short toxins with MMP2 and Annexin A2 
ClusPro programme (https://cluspro.org) was used to dock activated MMP2 (1CK7-A-) 
and AnxA2 with CA4, CTX23 and Cltx-like peptide AaCTX as described previously in 
3.2. The top cluster (with the highest number of members) was downloaded in PDB 
format and then analysed using Swiss Deep-View and PyMOL. The energy score 
profile of the top cluster was downloaded in order to study binding affinity of peptide-
protein complex. The PDB file of the top cluster was visualised in PyMOL programme 
at 20 Angstroms. Surface representation was selected for receptor protein and stick 
representation was selected for ligand toxin. Residues of ligands that were contacting 
with residues of receptor protein was coloured and labelled.  
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4.3 Results.  
4.3.1 Comparison of primary structure of Cltx-like short toxins 
In order to compare the primary structures of all known Cltx-like short toxins, amino 
acid sequences were extracted from UniProt, GeneBank, TrEMBL, EMBL-EBI and 
the primary literature. Primary sequence alignment of 34 Cltx-like short toxin peptides 
is shown. Sequence alignment reveals that chloride channel toxins show high 
sequence homology to chlorotoxin, 8 conserved cysteine residues form a common 
disulphide bridge scaffold.  
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Chlorotoxin (P45639)              -MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR---       36 
CTX23 (Xu et al., 2016)            VCMPCFTTDQQMARKCSDCCGGKGRGKCYGPQCLCR-         36 
CA4 (Xu et al., 2016)              -CGPCFTTDHNMARKCDECCGGKGRGKCFGPQCLCR-         35 
Neurotoxin MeuCltx (P86401)        MCMPCFTTDHNMAKKCRDCCGGN--GKCFGYQCLCNRG-       39 
Insectotoxin I4 (P60269)          -MCMPCFTTDHNMAKKCRDCCGGN--GKCFGPQCLCNR--       35 
Insectotoxin I5A (P15222)         -MCMPCFTTDPNMAKKCRDCCGGN--GKCFGPQCLCNR--       35 
BS Tx7 (Ali et al., 2016)          -CGPCFTTDWESEKKCAECCGGIGR--CFGPQCLCNRK        35 
Toxin Lqh 8/6 (P55966)            -RCSPCFTTDQQMTKKCYDCCGGKGKGKCYGPQCICAPY-       38 
SMALL Toxin (P15229)              -RCKPCFTTDPQMSKKCADCCGGKGKGKCYGPQCLC----       35 
Cltx-like Peptide MeICT (F1DI80)  -MCMPCFTTDHNMAKKCNDCCGGY--GKCFGPQCLCR---       34 
Insectotoxin I1 (P15220)          -MCMPCFTTRPDMAQQCRACCKGR--GKCFGPQCLCGYD-       36 
Cltx-like peptide BS14 (P59887)    -CGPCFTKDPETEKKCATCCGGI--GRCFGPQCLCNRGY       36 
Insectotoxin I5 (P60270)          -MCMPCFTTDPNMANKCRDCCGGG--KKCFGPQCLCNR--       35 
Insectotoxin I3 (P60268)          -MCMPCFTTDHQTARRCRDCCGGRGR-KCFG-QCLCGYD-       36 
Toxin Gatx1(P85066)                -CGPCFTTDHQMEQKCAECCGGI--GKCYGPQCLCNR--       34 
Neurotoxin P2 (P01498)             -CGPCFTTDPYTESKCATCCGGR--GKCVGPQCLCNRI-       35 
Cltx-like peptide AaCTX (P86436)  -MCIPCFTTNPNMAAKCNACCGSR-RGSCRGPQCIC----       34 
Neurotoxin MeuCltx-1 (P86402)     -MCMPCFTTRPDMAQQCRDCCGGN--GKCFGYQCLCNR-------- 35 
Venom CL Chnl Toxn2 (E4VP46)       MCMPCFTTRPDMAQQCRDCCGGN--GKCFGYQCLCNRGRIVIMYT 43 
Cl Chnltox-like Pep1b (R4H559)     MCMPCFTTRPDMAQQCRDCCGGN--GKCFGYQCLCNRG------- 36 
Cl ChTox-like pep1a (R4H5A4)       MCMPCFTTRPDMAQQCRDCCGGN--GKCFGYQCLCNRG------- 36 
Vnm CL ChTox-1 (E4VP45)            MCMPCFTTRPDMAQQCRDCCGGN--GKCFGYQCLCNRG------- 36 
Cltx-1 (A0A023UFA0)                MCMPCFTTNLNMEQECRDCCGGT--GRCFGPQCLCGYD------- 36 
BMK CT (Q9UAD0)                   -GCGPCFTTDANMARKCRECCGGI--GKCFGPQCLCNRI-       36 
BM12-b (Q9BJW4)                   -GCGPCFTTDANMARKCRECCGGN--GKCFGPQCLCNRE-       36 
Cltx-2 (A0A023UGK1)                MCMPCFTTRPNMAQQCRDCCRGR--GKCFGPQCLCGYD------- 36 
Cltx-3 (A0A023UH07)                MCMPCFTTRPNMAQQCRDCCRGR--GKCFGPQCLCGYD------- 36 
BTITx3 (P83400)                   -RCPPCFTTNPNMEADCRKCCGGR--GYCASYQCICPGG-       36 
U14 Hottox-Hj1A                   -RCPNCFTTNPNAEADCKKCCGNRW-GKCAGYQCVCPMK-       37 
Lep-S Tox (P81761)                -RCGPCFTTDPQTQAKCSECCGRKG-GVCKGPQCICGIQY-      38 
I6 Tox (A0A0D4CYV3)                GCMPCFTTDRYMARKCKECCRGY--GNCFGPQCLCNRG        36 
I4 Tox (A0A0D4CZV2)                MCMPCFTTDHNMAKKCRDCCGGN--GKCFGPQCLCNRG-       36 
Tx16 (B8XH23)                      ACAPCLPGDFLRDKKCKACCGGN--GKCMGISCRCSGGSKS---- 39 
Tx12 (B8XH27)                      SCTTCFSTTPNMDKICSNCCRNKGGGTCKGSYCVCRIQY------ 39 
      2  5    10     16    20   23   27 29    33   36 
 
 
Figure 4.1 Primary Sequence alignment of Cltx-like short toxins. Amino acids are colour 
coded based on their properties. Positive residues are highlighted blue, negative residues 
are highlighted red, amino acids with polar side chains are highlighted green and residues 
with non-polar side chains are highlighted grey. Conserved cysteine amino acids are 
highlighted yellow and aromatic amino acids are highlighted magenta. Yellow arrows on top 
of sequences represent three β-sheets and the α-helix is represented by a red cylinder. 
Disulphide bridge pattern is represented by black lines linked between C1-C4, C2-C6, C3-
C7, C5-C8. Where identified signal peptide (from cDNA) have been removed.   
 
 
 
 
 
 
 
 
Toxin PDB code Sequence Number of 
Amino 
acids 
 
3 1 2 4 5 6 7 8 
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All Cltx-like short toxins share highly conserved cysteine residues which produce four 
disulphide bridges. Number of amino acids is constant between Cys1-Cys2-Cys3-
Cy4, though the number of amino acids varies between Cys5-Cys6 and Cys6-Cys7, 
Csy8 at C-terminal domain is variable. There is a semi-conserved PCFTx motif at N-
terminal domain, present in all toxins except Tx12, Tx16 and U14 hottentoxin-Hj1a 
(Fig 4.1). Cltx-like peptide Bs14 has a positive residue Lys at position 7 instead of a 
polar residue Thr7.  
Semi-conserved region at C-terminal domain ‘GPQCxC’ is present in all toxins 
except BtITx3, I6 toxin, U14 Hottentoxin-Hj1a, Tx16 whereas, an aromatic residue 
Tyr31 is present instead of Pro29 in Neurotoxin MeuCltx, Neurotoxin MeuCltx-1, 
Venom chloride channel toxin-1 and 2, Chloride channel toxin-like peptide 1a and 1b 
(Fig 4.1). A positive residue Arg is present at the C-terminal domain of Cltx and other 
toxins except small toxin, toxin Lqh 8/6, I1, I3, Cltx-like peptide AaCtx, Cltx-1, 2 and 
3, BtITx3 as well as Lepidopteran-selective toxin. Lysine is present at C-terminal 
domain instead of Arg in U14 Hottentoxin-Hj1a and Tx16. Positive residues Lys25 
and Lys27 is conserved in Cltx and many other toxins except BtITx3, Lepidopteran 
selective toxin, TX12 and I6 toxin and Cltx-like peptide. Positive residues Arg14 or 
Lys14 and Lys15 are conserved in many toxins, giving chloride channel toxins a 
stronger positive charge. Cltx and many other toxins also has a conserved negative 
Asp9 amino acid (Fig 4.1). Sequence similarity between toxin peptides indicates the 
possibility of similar structure and function. Although, sequences of many Cltx-like 
short toxins have been determined, only a few toxins have been used in glioma. To 
date, 3D structures of Cltx and I5A has been experimentally determined and 
available in PDB-databank (DeBin et al., 1993; Arseniev et al., 1993). There is a 
difference of 10 amino acids between Cltx and BMK CT whereas, CA4 and CTX23 
has a difference of 5 and 3 amino acids from Cltx respectively which may represent 
difference in loop orientation. Cltx-like peptide AaCTX is a 34 amino acids peptide 
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and it shares 61% sequence identity to Cltx. Both CA4 and CTX23 share 78% and 
85% sequence similarity to Cltx. In present study, secondary structure analysis by 
PSIPRED showed that all toxins share similar secondary structure to parent Cltx and 
Insectotoxin I5A containing 2 extended β-sheets and one small fragment of β-sheet 
as well as an α-helix.  
Cltx is a 4002Da and the peptides observed masses of all Cltx-like short toxins range 
between 3598Da and 4173Da. Cltx is a basic peptide at physiological pH with a PI of 
8.5 and most other toxins have similar PI values 8.5 (±0.50) except Cltx-1 and Gatx1 
with a PI values of 4.32 and 6.69 respectively. Hence, all Cltx-like short toxins are 
positively charged with exception of Cltx-1 and Gatx1. Sequence homology ranges 
between 48-100%. CA4 and CTX23 were selected for further docking studies.  
 
 
 
                                       
 
Chlorotoxin (P45639)              -MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR---       36 
CTX23   Xu et al., 2016            VCMPCFTTDQQMARKCSDCCGGKGRGKCYGPQCLCR-         36 
CA4     Xu et al., 2016            -CGPCFTTDHNMARKCDECCGGKGRGKCFGPQCLCR-         35  
Cltx-like peptide AaCTX (P86436)  -MCIPCFTTNPNMAAKCNACCGSR-RGSCRGPQCIC----       34 
                                        2  5    10     16    20   23   27 29    33   36 
Figure 4.2. Sequence alignment of Cltx, CTX23, CA4 and Cltx-like peptide AaCTX. 
Amino acids are colour coded in CINEMA colour scheme. Three β-sheets are shown by 
yellow arrows and the α-helix represented by a red cylinder.  
 
 
 
 
 
 
 
 
 
 
 
 
Toxin PDB 
code 
Sequence Amino 
acids 3 1 2 
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All 4 peptides share semi-conserved region motif ‘PCFTT’ at N-terminal domain and 
‘GPQCxC’ at C-terminal region of toxin sequences. CA4 has a truncated N-terminus 
beginning with Cys1. Aromatic residue Phe6 is highly conserved in all four Cltx-like 
toxins (Phe5 in CA4). Both Cltx and CTX23 share conserved positive Arg14, Lys15 
amino acids and Lys23, Arg25 as well as Lys27 except Cltx-like peptide AaCTX. CA4 
contains conserved positive residues Arg13, Lys14, Lys22, Arg24 and Arg35.  
 All peptides share Arg35- Arg36 at C-terminal domain except Cltx-like peptide 
AaCTX. Cltx-like peptide AaCTX has a Cys amino acid at position 34 at C-terminal 
domain but contains Arg at position 23, 24 and 28. Negative residues Asp17 and 
Asp18 are located on α-helix of Cltx and Asp16 and Glu17 are present in CA4, 
Interestingly, CTX23 has a polar residue Ser at position 17 whereas, Cltx-like peptide 
AaCTX has polar a residue Asn17 and a non-polar residue Ala at position18. There 
is no single negative residue present in Cltx-like peptide AaCTX indicating a strong 
positive charged surface of toxin. Both Cltx and CTX23 has an aromatic residue Tyr 
at position 29 though CA4 has Phe at position 28 indicating a neutral region around 
this region of the peptide. However, Cltx-like peptide AaCTX contain a positive 
residue Arg at position 28 indicating a positive charged region around this area. 
Hydrophobic residues Gly 30, Pro31, Leu34 located of toxins peptide and this motif 
is conserved in many other toxins (Fig4.2). 
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 4.3.2. Comparison of 3D models of Cltx-like short toxins.  
 
3D models of CA4, CTX23 and Cltx-like peptide AaCTX were generated by 
homology modelling using Swiss-Model. 3D models of CA4 and CTX23 were 
generated based on Cltx template (PDB code: 1CHL), while Cltx-like peptide AaCTX 
was generated based on I5A template (PDB code: 1SIS). Subsequently, the quality 
of 3D models was assessed using QMEAN6, Z-Score, DFIRE energy and Procheck 
Ramachandran plot. The quality of 3D models was better than its parent Cltx 3D 
structure (See appendix). Superimposition of these models is shown in Fig 4.3. A 
cysteine stabilised α-helix (CSH) fold is linked by 3 disulphide bridges to extended β-
sheets and fourth disulphide bridge is linked to loop region. All 4 peptides share 2 
small anti-parallel β-sheets (arrows) and a small fragment of β-sheet in extended 
loop as well as an α-helix. Cltx-like short toxins share CSH structural scaffold 
stabilised by disulphide bridges which gives toxin a compact structure and stability.  
A ribbon representation of superimposed toxins using Swiss Deep-View. All toxins 
superimpose perfectly as shown in Fig 4.3 The α-helix of Cltx-like peptide AaCTX is 
slightly longer than Cltx, CTX23 and CA4. Blue arrows show that there is small 
deviation between loop region of Cltx-like peptide AaCTX as compared to other 
toxins.  
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Figure 4.3. Superimposition of Cltx, CA4, CTX23 and Cltx-like peptide AaCTX 
represented by ribbon display. Superimposed structures of Cltx (yellow), CA4 (blue) and 
CTX 23 (green) and Cltx-like peptide AaCTX (red) is shown in Figure above. Blue arrows 
show difference in structures of different toxins.  
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Stick representation of superimposed models of Cltx-like short toxins is shown in Fig 
4.4. Important residues that are conserved in Cltx, CA4, CTX23 and Cltx-like peptide 
AaCTX are labelled, and location of amino acids overlay accurately. The locations of 
amino acids differ between the four peptides are indicated with red arrows.  
Aromatic residue Phe6 (Phe5 in CA4) overlaid accurately in four short toxins.  Cltx-
like peptide AaCTX contains Asn9 that is overlaid accurately on Asp9 of Cltx, CTX23 
and Asp8 of CA4. A non-polar residue Ala14 and positive residue Lys15 of Cltx-like 
peptide AaCTX superimposed on Arg14, Lys15 of Cltx, CTX23 and Arg13, Lys14 of 
CA4 toxin (Fig 4.4). Notably, Arg23 of Cltx-like peptide AaCTX is not overlaid on 
Lys23 of Cltx, CTX23 or Lys22 of CA4. Negative residues such as Asp16 of CA4 and 
Asp17 of Cltx are overlaid perfectly, Where, Ser is present at position 17 in CTX23 
and Asn is present at position 17 in Cltx-like peptide AaCTX. All residues are overlaid 
at similar position as labelled by red arrows in Fig 4.4. Cltx, CTX23 and CA4 has a 
negative residue at position 18 that is superimposed at similar place to each other 
and Ala18 of Cltx-like peptide AaCTX. Arg25 is superimposed perfectly, but there is 
slight deviation between aromatic ring of Tyr29 of Cltx, CTX23 and Phe28 of CA4. 
There is a slight difference between Arg28 of Cltx-like peptide AaCTX and Phe28 of 
CA4. Overall, amino acids residues of all 3D models superimpose accurately hence 
representing similar 3D structure.   
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Figure 4.4. Superimposition of 3D structures of Cltx, CA4, CTX23 and Cltx-like peptide 
AaCTX by Swiss Deep-View. 3D structure of Cltx is coloured yellow, 3D models of CA4, 
CTX23 and Cltx-like peptide AaCTX are coloured green, blue and grey respectively. 
Important conserved amino acids in all four peptides are labelled, different amino acids of 
each toxin that are superimposed at similar position identified using arrows red arrows.  
 
 
 
 
 
 
 
 
ARG2
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The electrostatic surfaces of Cltx, CA4, CTX 23 and Cltx-like peptide AaCTX were 
calculated using Swiss Deep-View. Analysis of electrostatic surfaces of 3D structure 
of Cltx show a wide distribution of positive charge on its surface created by positive 
side chains (Arg, Lys) that possibly interact with ion channels and putative MMP2 
receptor. Positive residues such as Arg, Lys exposed on α-helix of Cltx, CA4 and 
CTX23 giving toxins a strong positive charge. A Positive residue Lys27 is located on 
second β-sheet that is present on solvent accessible face of toxins that may have 
involvement in interaction with ion channels. Negative residue Asp9 of Cltx, CTX23 
or Asp8 of CA4 is responsible for negatively charged surface around N-terminal loop 
region. However, Cltx-like peptide AaCTX does not contain this negatively charged 
surface at loop region as it has a polar residue Asn9 instead of a negative residue.  
Hydrophobic surface (neutral) can be visualised near loop region before N-terminal 
domain of α-helix as well as near 3rd β-sheet of toxins. Overall, all 3 toxins have a 
strong positive electrostatic surface particularly near C-terminal domain of toxins.  
Both Cltx and CA4 have strong negative region around α-helix due to Asp17Asp18 
and Asp16Glu17 but CTX23 has Ser17 and only one negative residue D18 around 
α-helix hence weaker negative charged surface in this region. In contrast, Cltx-like 
peptide AaCTX does not have negative region at all around α-helix as it has Asn17 
and Ala18 instead of negative residues. Hence this region contains overall positive 
charged region possibly due to adjacent Arg23. Moreover, Cltx-like peptide AaCTX 
does not have a negative residue Asp8 or Asp9 but has a polar residue Asn9 at loop 
region (encircled red in Figure 4.5). Positive charged surface of the C-terminal 
domain of Cltx, CA4 and CTX is contributed by Arg35 or Arg36 whereas, Cltx-like 
peptide AaCTX has Cys34 at C-terminal domain and a slight neutral region around 
C-terminal region. Cltx, CA4 and CTX23 has an aromatic residue at position 28 or 29 
contributing towards a slight neutral region. Cltx-like peptide AaCTX contain Arg28 
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creating a stronger positive charged surface around β-sheets of the toxin. Second β-
sheet of Cltx, CA4 and CTX23 contains Lys26 or Lys27 residue hence contributing to 
a highly positive charged region around this region. The Cltx-like peptide AaCTX 
contains a polar residue Ser at position 26 thus does not have a highly positive 
charged surface around this region as compare to Cltx, CTX23 and CA4 toxins. 
Overall, all four toxins contain a highly positively charged surface area around 
peptide surfaces. Cltx, CA4 and CTX23 contain negative and neutral regions 
particularly around loop regions, while Cltx-like peptide AaCTX as a stronger positive 
charged surface due to lack of negative residues. 
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4.3.3 Docking of chlorotoxin-like short toxins 
Chlorotoxin is a promising toxin for inhibiting glioma metastasis. It is a potential toxin 
for targeting MMP2 and AnxA2 that are over-expressed in glioma. Cltx homologues 
have potential use in glioma as they share sequence homology to Cltx.  
Chlorotoxin-like short toxins CA4, CTX23 and Cltx-like peptide AaCTX are relatively 
important and clinically significant toxins. Biological function of these toxins has been 
studied and they inhibited glioma metastasis (Xu et al., 2016). We docked CA4, 
CTX23 and Cltx-like peptide AaCTX to their putative binding partners that is MMP2 
and Annexin A2 in order to study their interaction and their effects with a view that 
these toxin peptides would help to understand the mechanism of action of Cltx.  
 
4.3.3.1 Molecular docking of Cltx-like short toxins with MMP2. 
MMP2 without activation peptide was docked to CTX23, CA4 and Cltx-like peptide 
AaCTX in order to study toxin interaction with putative receptor. This generated a top 
cluster of peptide-MMP2 conformations with the highest number of members bound 
at similar positions indicating near-native solutions. Top clusters and their energy 
scoring function were obtained in order to analyse accurate prediction of binding 
affinity of the peptide-protein complex.  
Results show that CTX23 binds to MMP2, the top cluster of CTX23-MMP2 complex 
shows that CTX23 interacts with the catalytic domain of MMP2 (Fig 4.6.1). 
Interestingly, bound conformation is similar to that of Cltx. CTX23 is bound near α-
helices and loop regions of the catalytic domain. CA4 toxin was docked to MMP2 to 
study their interaction, results show that CA4 binds to MMP2 as the top complex 
reveals that CA4 is bound to MMP2 at the catalytic domain. Analysis of the top 
clusters reveals that CTX23 is bound near α-helices particularly helix-b and extended 
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peptide region of the catalytic domain (Fig4.6.1). Similar binding orientation is 
favoured by both CTX23 and CA4 to MMP2 in the top clusters. Cltx also binds to 
similar locus on activated MMP2 like both CA4 and CTX23 do. Cltx-like peptide 
AaCTX also interacts with MMP2, top1 cluster of Cltx-like peptide AaCTX and MMP2 
shows that peptide is interacting with the catalytic domain of MMP2. Although, Cltx-
like peptide AaCTX is docked slightly different to MMP2 catalytic domain than CTX23 
and CA4 as α-helix of toxin is bound very closely to all 3 α-helices of the catalytic 
domain (Fig4.6.1).  
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Figure 4.6.1. The top docked clusters of Cltx-like short toxins and MMP2.  
MMP2 without activation peptide and point mutation docked to (a) CTX23 toxin peptide, (b) 
CA4 toxin peptide (c) Cltx-like peptide AaCTX. Α-helices of MMP2 are coloured cyan, β-
sheets and loops are coloured magenta. Cltx-like short toxins are highlighted by a circle, α-
helices of toxins are coloured red while β-sheets are coloured yellow. (a) CTX23 is bound to 
the catalytic domain of MMP2, interestingly, similar face of CA4 is also bound to the catalytic 
domain of MMP2. However, orientation of Cltx-like peptide AaCTX is slightly different to both 
CA4 and CTX23.  
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Binding between CTX23 and MMP2 the top complex was studied in order to examine 
amino acids that may have involvement in interaction between peptide and MMP2. 
The surface constituted by β-sheets and loop region of the C-terminal domain of 
CTX23 interacts deeply with MMP2. Positive residues of CTX23 particularly, Arg36 is 
present in close contact with Glu296 of MMP2, Arg25 is in close contact with Asp77. 
Also, Lys27 of CTX23 is present in close proximity of Glu109 of MMP2. Although, 
aromatic amino acid Tyr29 of CTX23 is in close contact with Thr318 of MMP2 as 
shown in Figure below (Fig 4.6.2). Interestingly, Arg14 or Lys15 are situated in free 
space away from MMP2 target. As shown earlier, CTX23 toxin contains a wide 
distribution of positive charge around its surface. This indicates the importance of 
positive residues that possibly have strong binding interaction with negatively 
charged MMP2. Non-polar residues such as Leu34, Cys35 are also present in 
proximity of the CAT domain of MMP2.  
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Figure 4.6.2. Interaction the top complex of CTX23 and MMP2 produced by PyMOL. (a) MMP2 is 
coloured green and CTX23 is coloured turquoise. Possible Interacting residues between CTX23 and 
MMP2 are represented by circles. Amino acids of CTX23 that are interacting with MMP2 are coloured 
orange while interacting amino acids of MMP2 are coloured red (b) MMP2 is shown as grey surface 
and CTX23 is shown as cyan.  
MMP2  
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Although, positive residues of toxin CTX23 particularly near C-terminal domain are 
present in close contact with negative residues of MMP2, Arg14 and Lys15 of α-helix 
does not interact with MMP2 as shown in Fig4.2.2. Majority of residues, particularly 
positive residues of β-sheets in C-terminal domain are present deeply in pockets of 
MMP2 interacting with negative residues. Some non-polar residue that are part of C-
terminal semi- conserved motif ‘GPQCxC’ are also present in close proximity of 
MMP2.  
 
                    
Figure 4.6.3. Show interaction of CA4 peptide with MMP2 target. MMP2 is shown in 
green and CA4 is shown in cyan. Residues of interest of MMP2 are highlighted in red while 
residues of toxin are highlighted as orange. Important residues of peptide-protein are 
highlighted in red circles.  
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According to the top complex, Arg24 of CA4 is present in close contact of Asp77 of 
MMP2, Lys22 contacts with GLU304, Arg35 interacts with Glu296 and Lys26 lie 
close to Asp308 which represent electrostatic attractions between two molecules. 
Aromatic residue Phe28 of CA4 is close to Thr318 of MMP2. Tyr29 of CTX23 was in 
close contact with Thr318 of toxin indicating important role of this particular aromatic 
residue in interaction. Similar to CTX23-MMP2 complex, Arg13 and Lys14 of CA4 
that are located in helix region of CA4 does not interact with MMP2.  
 
 
Figure 4.6.4. Interaction of residues between Cltx-like peptide AaCTX and activated 
MMP2. Cltx-like peptide AaCTX is coloured cyan and residues of interests of the peptide are 
shown in orange colour. Where, MMP2 target is coloured as green and residues of interests 
of MMP2 are coloured in red.  
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The C-terminal domain including β-sheets just before α-helix of the peptide is 
interacting with MMP2. Although Cltx-like peptide AaCTX does not contain Arg35 or 
36 of CA4, CTX23 and Cltx at C-terminus, Arg23 interacting with Asp77 while Arg24 
is interacting with Glu296.  Hydrophobic residues such as Gly29, Pro32 and Cys30 
are buried deep within MMP2 domain. Hence, positive residues do play important 
part in interaction with MMP2 along with hydrophobic residues on C-terminal domain 
of the toxin.  
 
4.3.3.2 Energy Scoring of docked complexes of peptide-MMP2. 
The energy scoring provides stability and binding affinity of docked complex of 
peptides and target. Most likely, near-native confirmation is determined by cluster 
size, that is the highest number of docked neighbour structures within a cluster and 
with the lowest energy. Lowest energy regions tend to predict bigger cluster of 
docked complexes. The top cluster contain large cluster energy profile table of top 
docked cluster is given below. According to data, the top cluster of CA4 has highest 
number of docked structures that include 261 members and the energy of the cluster 
centre is -762. CA4/MMP2 docked structure in cluster 1 has the lowest energy of -
965.5.  Lowest energy of this structure is within similar range of Cltx-MMP2 complex 
which has lowest energy of -956.50. Although, cluster size of Cltx-MMP2 complex is 
smaller than cluster size of CA4-MMP2 complex. CA4, like Cltx is bound stably at the 
CAT domain of MMP2.  
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Table 4.6.5. Energy score profile of top1 clusters of docked toxin-MMP2 structures. 
Members represents size of the docked complexes, that is number of docked structures 
within a cluster, energy of cluster centre represents energy of docked complex that has the 
highest number of members or neighbours in the cluster and energy of the docked complex 
in cluster with lowest energy.  
 
The top cluster of the CTX23-MMP2 complex show stable binding affinity with large 
number of members present in cluster1. Cluster 1 of CTX23-MMP2 contain 165 
members with centre energy of -680 and lowest energy of structure is -762. CTX23 
also has stable binding to MMP2, though CA4 and Cltx binds strongly to the CAT 
domain of MMP2.  
Although, Cltx-like has a strong binding affinity to MMP2 with -688 energy of cluster 
centre and lowest energy of structure in the cluster is -802, size of cluster is much 
small than CA4, CTX23 and Cltx. As cluster has smaller size, Cltx-like peptide 
AaCTX may not represent a strong binding affinity to the CAT domain of MMP2.  
 
Toxin peptide Cluster Members Representative Weighted Score 
CTX23 1 165 Centre -680 
Lowest energy -850 
CA4 1 261 Centre -762 
Lowest energy -965.5 
Cltx-like peptide  
AaCTX 
1 127 Centre -688 
Lowest energy -802 
Cltx 1 183 Centre -709.5 
Lowest energy -956.5 
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 4.3.4 Docking of Chlorotoxin-like short toxins to human Annexin A2.  
Cltx was shown to bind to MMP2 and thus inhibits glioma proliferation and 
metastasis (Deshane et al., 2003). Later, Kesavan et al., (2010) suggested that Cltx 
binds to AnxA2 thus inhibits angiogenesis and glioma metastasis. Cltx homologues 
CTX23, CA4 and Cltx-like peptide AaCTX were docked to human annexin A2 to 
study their binding interaction with annexin A2. 3D structure of human annexin A2 
(PDB code: 2HYW, chain A) was determined by X-ray diffraction at 2.10Å by Shao et 
al., (2006). 2HYW contains homologous repeats (I-IV) arranged in a near-parallel 
shape, starting from Asn31 to Asp338. All homologous repeats contain 5 α-helices and 
are structurally similar to each other making a curve-shaped disk structure (Shao et 
al., 2006). 2HYW share structure similarity to human AnxA2 (PDB code: 1XJL), both 
2HYW and 1XJL contain 7 Ca bound ligands.  
All three Cltx-like toxins bind to AnxA2. Top docked structure that contains the 
highest number of docked neighbour structures was examined. The top cluster show 
CTX23 binds to AnxA2, particularly, beginning of the N-terminal domain, β-sheets 
and the C-terminal domain of CTX23 are interacting with helices of repeat-I and IV of 
AnxA2 (Fig 4.7). The α-helix of CTX23 does not interact with AnxA2 and the helix 
region is not located near the surface of AnxA2. Similar binding pose is observed in 
that of Cltx-AnxA2 complex. Though, the top cluster of CA4 and Cltx-like peptide 
AaCTX show that both peptides are bound to repeat I and II of AnxA2, however, with 
different orientation (Fig4.7).  
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Figure 4.7. Docking of Cltx-like short toxins to human AnxA2. (a) The top bound cluster 
of CTX23, CA4 and Cltx-like peptide AaCTX with AnxA2, α-helices and loops of AnxA2 are 
coloured in cyan and magenta respectively. CTX23 is highlighted in a red circle, the α-helix 
of CTX23 is coloured red and β-sheets are coloured yellow. Black arrow shows that both 
CA4/AnxA2 and Ctx-like peptide/AnxA2 complexes have a slight orientation difference to 
CTX23/AnxA2 cluster. 
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Both CA4 and Cltx-like peptide AaCTX bound to similar region of AnxA2, though 
bound with different orientation. The CTX23 is bound to repeat I and IV of AnxA2 
whereas, CA4 and Cltx-like peptide AaCTX are bound to repeat I and II of AnxA2. 
 
 
Figure. 4.7.1. CTX23 and AnxA2 interaction in the top complex. Protein surface of 
AnxA2 is shown in beige and ribbon structure of CTX23 toxin are shown in cyan and amino 
acids of toxin peptide is labelled.  
 
CTX23 interacts with AnxA2 particularly Met1 of C-terminal domain and hydrophobic 
residues such as Leu34at Gly30, Pro31 and Leu34 as well as Cys35 of C-terminal 
domain are interacting deeply with pockets of repeat I and IV of AnxA2. Positive 
residues such as Arg36 is in close contact with repeat-I and Arg25 and Lys27 are 
interacting with repeat-IV of AnxA2. Note that Lys15 of toxin does not interact with 
the peptide, a region before α-helix of CTX23 is freely accessible as it is not 
interacting with AnxA2 peptide.  
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Similar docking pose is observed in Cltx-AnxA2 the top confirmation, where Cltx 
binds to repeat I and IV as well. However, CA4 binds to different region on AnxA2 
despite being highly homologous to parent Cltx. Cltx-like peptide AaCTX also binds 
to AnxA2 at similar repeats as CA4 but both toxins are bound to target with different 
orientation (Fig4.7.1).  
 
Figure. 4.7.2. Interaction of CA4 and Cltx-like peptide AaCTX to human AnxA2. (a) 
Surface of AnxA2 is represented by beige colour and stick structure of CA4 is represented 
by sticks. Amino acids of interests are labelled. (b) Similarly, surface of AnxA2 is shown in 
beige and stick representation of Cltx-like peptide AaCTX is shown as cyan. Amino acids 
that are interacting with AnxA2 are labelled. 
 
Both CA4 and Cltx-like peptide AaCTX are docked to AnxA2 with different orientation 
although both are interacting with repeats I and II of AnxA2. Cys1, Pro3 of CA4 at C-
terminal domain are in present in deep cavities of AnxA2, Arg35, Lys26 and Phe28 
are also interacting with AnxA2. However, Arg 13 and Lys22 residue of CA4 does not 
interact with target. In contrast, Arg23 and Arg24 of Cltx-like peptide AaCTX interact 
with AnxA2 as well as Ile33 and a positive residue Arg28 is interacting with AnxA2.  
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Binding affinity and stability of these docked confirmation is determined by cluster 
size and energy scoring. Initial data of energy scoring show that Cltx-like short toxins 
interacts with AnxA2 although, binding affinity is weaker as compared to that of toxin-
MMP2 docked complexes (Fig4.7.2). Similar binding affinity for Cltx-AnxA2 was 
observed in the top cluster. Weighed energy scores for all the top clusters of short-
toxins are shown in table below. Top1 clusters of all short toxins contain largest 
number of members with centre energy of the centre complex and lowest energy of 
the structure in the cluster. Results show that CTX23 interacts with AnxA2 with a 
stable binding complex, the top cluster of CTX23-AnxA2 contain 234 neighbours in 
cluster centre. Energy of the cluster centre is -507 and lowest energy is -609 of 
structure complex in the top cluster. Binding stability of CTX23-AnxA2 is in similar 
range to Cltx-AnxA2 the top cluster which have 289 members and -635.5. However, 
CA4 has lowest number of member as compared to Cltx and CTX23 when docked to  
AnxA2, although, all members have stable confirmation with lowest energy of -581. 
Hence there is no significance difference between energy profiles of the docked 
complexes. However, there is slight variation in cluster sizes. As mentioned before, 
the large docked cluster with lowest energy represent near-native structures and 
have been validated with good acceptable scoring via CAPRI. 
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Peptide-AnxA2 
complex 
Cluster Members Representative Weighted Score 
CTX23/AnxA2 1 234 Centre -507 
Lowest energy -609 
CA4-AnxA2 1 168 Centre -450 
Lowest energy -581 
Cltx-like peptide Aa
AnxA2 
1 190 Centre -475 
Lowest energy --561.5 
Cltx-AnxA2 1 289 Centre -575.5 
Lowest energy -635.5 
 
Table 4.8 Energy scoring for Cltx-like short toxins and AnxA2 the top clusters. The top 
cluster has highest number of members (neighbours docked structures). Members represent 
size of the docked complexes, that is number of docked structures within a cluster, energy of 
cluster centre represents energy of docked complex that has the highest number of 
members or neighbours in the cluster and energy of the docked complex in cluster with 
lowest energy.  
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4.5 Discussion 
Cltx was initially shown to inhibit small-conductance epithelial chloride channels 
(DeBin et al., 1993). More recently MMP2 and subsequently AnxA2 were proposed 
potential targets for Cltx (Deshane et al., 2003; Kesavan et al., 2010). The CA4, 
CTX23, Cltx-like peptide AaCTX share evolutionary structural relationship and 
possibly have same molecular targets as there is a high degree of sequence 
homology between toxins. Although, functional studies of these and other family 
members are extremely limited or non-existent. Our results of secondary structure 
analysis show that all toxins share 8 highly conserved cysteine residues that give 
toxins a compact structure, all toxins consist of three β-sheets packed around α-helix 
and stabilised by disulphide bridges. Our study shows that electrostatically, all toxins 
have a highly positive charged surface. Hence, this represent their primary role in 
interaction with their putative targets. Since, 3D structures of only Cltx and I5A have 
been determined to date (Arseniev et al., 1993; Lippens et al., 1995), homology 
modelling was used to predict 3D models of toxins and then investigated in docking 
studies. Three toxins were selected and homology modelling show that they share 
similar structure as majority of residues are conserved in each toxin and residues 
superimpose well. In the present study, docking results show that structural motif of 
β-sheets and loop region at the C-terminal domain in CTX23, CA4 as well as Cltx-
like peptide AaCTX toxins bound to the targets in majority of top complexes which 
represents the structural similarities and the way toxin might affect their targets in a 
similar way in-vivo.  
Docking results show that CTX23 and CA4 binding with MMP2 is slightly stronger 
and have large docked members within the top cluster as compared to Cltx-like 
peptide AaCTX. There is no big difference between binding energy of Cltx-like 
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peptide AaCTX to other toxins. Although, the number of members in the top cluster 
is very small as compared other short toxins. Results correlates with the 
experimental studies performed by Rjeibi et al., (2011) as they showed that Cltx-like 
peptide AaCTX showed less than 10% activity on glioma than Cltx. As mentioned 
before that the large cluster with lowest energy tend to have a near-native structure 
in top cluster. Results show that positive residues at the C-terminal domain such as 
Lys27, Arg36 interact with negative MMP2 target which represent electrostatic 
interaction between two proteins. Our results show that Cltx-like peptide AaCTX 
lacks Lys27 and a positive residue at the C-terminal domain which might be involved 
in weaker binding to its target MMP2 than other Cltx-like short toxins. Hence, lack of 
some important positive residues in sequence might play a role in weaker binding 
and smaller cluster size.   
Moreover, binding pose of CTX23 and CA4 with MMP2 is similar to Cltx-MMP2 
complex which represent a similar binding site on their target protein. Possibility of 
the evolutionary relationship between these short toxin peptides at the sequence 
level as well 3D level implies that the interaction model with target MMP2 is 
conserved.  
Our results suggest that the interaction between Cltx-like short toxins and activated 
MMP2 is much stronger than Cltx-like short toxins interaction with AnxA2. Top 
clusters of toxin-MMP2 show larger cluster size and very stable complexes within the 
cluster. There is a difference between energy values of the top clusters of CA4, 
CTX23 docked to MMP2 than CA4 or CTX23 docked to AnxA2. Soroceanu et al., 
showed that there is a high affinity site on glioma and a lower affinity site and they 
presumed the presence of more than one cellular targets for MMP2. Based on our 
results we assume that there is a possibility that the higher affinity binding site is 
MMP2 and lower affinity site AnxA2. As mentioned before, both MMP2 and AnxA2 
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are over-expressed in glioblastoma specimen and cells lines (Deshane et al., 2003; 
Lokman et al., 2011).  
The present study show toxin CTX23 and CA4 interact with their target MMP2, 
mainly via the β-sheets regions and loops near the C-terminal domain. The second 
β-sheet contain a highly conserved positive residue Lys27 (conserved in many Cltx-
like peptide AaCTX) as well as C-terminal Arg36; they play an important role 
interaction to MMP2 full-length and the catalytic domain of MMP2 as well as ionic 
channel (chloride channels). However, positive residues Arg14 and Lys15 do not 
interact with MMP2 directly. Mutation of these important residues might have 
significant effects on the way they interact with their targets.   
As one can visualise the results in this study, Cltx-like short toxins have a strong 
binding affinity to activated MMP2. Conserved positive residues especially at the C-
terminal domain as well as some hydrophobic residues play an important role in 
interaction which illustrate importance of electrostatic and hydrophobic interaction 
between two proteins Our results suggest that Cltx-like short toxins like their parent 
Cltx has lower binding affinity to AnxA2.  
This explains the evolutionarily relationship between these short toxin peptides and 
significance on their interaction with target MMP2 and AnxA2 is conserved.  Both 
CA4 and CTX23 have tendency to bind to both MMP2 and AnxA2 with strong binding 
affinity and share similar results as their parent Cltx. Cltx-like peptide AaCTX also 
has binding effects on MMP2 but lower binding than CA4 and CTX23. CA4 and 
CTX23 in glioma studies can be further evaluated in order to achieve a peptide toxin 
with great anti-glioma properties.  
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5 GENERAL DISCUSSION 
Cltx was shown to modulate small-conductance epithelial chloride channels (DeBin 
et al., 1993). Later studies showed that Cltx specifically binds to MMP2 but not 
MMP1 and MMP9 (Deshane et al., 2003). Later, Cltx was shown to facilitate 
internalisation of the lipid raft-anchored complex which contained MMP2, MT1-MMP, 
TIMP2 and ClC3 chloride channels thus inhibiting glioma metastasis (Kesavan et al., 
2010). To complicate matters further, AnxA2 was proposed a putative target for Cltx 
(Kesavan et al., 2010). Although, the mechanism of action of Cltx is unknown. Over 
the past few years, over 30 Cltx-like short toxins that share sequence homology to 
Cltx have been identified and they may have therapeutic potential in glioma and 
other cancers. It is very important to study these Cltx-like short toxins in glioma 
studies to find a suitable candidate with high potency for effective anti-glioma 
therapy. Although a few studies have attempted to study role of Cltx in glioma, there 
is an extremely limited data available about the structure-function relationship of Cltx 
and Cltx-like short toxins which needs to be investigated in order to understand the 
mechanism of action of Cltx and achieve a toxin that have higher binding affinity and 
greater efficacy.  
Recently, Cltx homologues CTX23, CA4 and Cltx-like peptide AaCTX have been 
tested in glioma studies (Rjeibi et al., 2010; Xu et al., 2016). Although, functional 
studies of their other family members are extremely limited or non-existent. The 
present study provides help to understand the mechanism of action of Cltx and 
provide a help for laboratory studies for a good therapeutic toxin selection.  
All Cltx-like short toxins adopted similar 3D structures identical to existing solved 
structures of Cltx and Insectotoxin I5A, suggesting their evolutionary relationship. 
Subsequent quality validation of predicted models by QMEAN6, Z-Score and 
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Ramachandran plots showed that all models had good quality and were comparable 
to relevant existing solved crystal structures. 
The present study show that Cltx has a higher binding affinity to native activated 
MMP2 than full-length MMP2. Results suggest that Cltx binds to the catalytic domain 
of MMP2 with a stronger binding interaction which might interfere the enzymatic 
activity of MMP2. Binding of Cltx to native activated MMP2 generated a top cluster 
containing 183 members and the cluster had a docked member with the lowest 
energy of -956.50 and a centre docked structure with the energy of -709.50. In 
contrast, the top docked cluster of Cltx and latent MMP2 consisted of 135 members 
which is a smaller cluster as compared to the top cluster of Cltx and native activated 
MMP2. Similarly, CA4, CTX23 and Cltx-like peptide AaCTX were bound near the 
active site of native activated MMP2 but with slightly different orientation. 
Interestingly, binding interaction of CA4 was very stronger than CTX23 and Cltx-like 
peptide AaCTX. The top cluster of native activated MMP2 and CA4 had a large size 
compared to Cltx, CTX23 and Cltx-like peptide AaCTX. The top cluster contained 
261 members and a member within that top cluster had the lowest energy of -965.50, 
suggesting a stronger binding interaction and a stable cluster. However, Cltx-like 
peptide AaCTX showed a weaker binding to activated MMP2 than CA4, CTX23 and 
Cltx. Our results suggest that Cltx, CA4 and CTX23 might block the catalytic site and 
thus inhibit enzymatic activity of MMP2.  
The present study suggest that Cltx has a higher binding affinity for MMP2 and lower 
for AnxA2. This supports a study conducted by Sorocenau et al., (1998) who 
proposed that Cltx has a high and a low affinity binding site on glioma cells. The 
present study also illustrates that Cltx and Cltx-like short toxins show binding 
interaction with MMP2 on a similar site but different sites on AnxA2 which suggests a 
high specificity and selectivity of toxins for MMP2. Thus, future studies can pay 
attention to the interaction of Cltx with MMP2 rather than AnxA2.  
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Analysis of residue interactions show that electrostatic interaction plays an important 
role in binding as the positive residues of Cltx and Cltx-like short toxins are present in 
close contact with negative residues of MMP2. A wide positively charged surface of 
Cltx and CTX23, CA4 and Cltx-like peptide AaCTX is created by positive residues 
such as Arg and Lys that possibly interact with negatively charged MMP2.  
Ullrich et al., (1993) showed that Cltx block glioma specific Cl- channels in acute 
slices of human glioma. Based on the electrostatic surface experiments in this study 
we can assume that charged residues may play an important role in inhibition of Cl- 
channels. Cltx may have interacted with the Cl- ion channels therefore likely that they 
would block a chloride channels by making a conformational change to the selectivity 
filter of a chloride channel rather than plugging it, which is positively charged. A study 
conducted by Jentsch et al., (2002) showed that ChTX plugs K+ channel thus 
blocking the activity of the channels.  
Our results show that the initial screen of all 34 Cltx-like short toxins docking 
suggests that they interact with MMP2. CA4 toxin has a strong binding interaction 
with activated MMP2 and Cltx-like peptide has a weak interaction. Although both 
MMP2 and AnxA2 have been proposed putative binding partners for Cltx, interaction 
of Cltx and Cltx-like short toxin is stable and stronger with MMP2 than AnxA2. The 
present study provides a help in selecting Cltx-like short toxins that have higher 
binding affinity with its putative target MMP2 and thus selecting toxins with higher 
efficacy for future laboratory studies. 
 
5.1 Limitation of current study and future directions.  
 
Protein structure is more stable and alters more slowly than its associated amino 
acid sequence during evolutionary process (Bloom et al., 2004). Evolutionary 
relationship between two proteins at the sequence level produces similar structures 
(Bloom et al., 2004). Studies showed that two completely different functioning 
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proteins may have similar structure due to evolution (Krieger et al., 2003). Homology 
modelling is an accurate and reliable method to predict 3D models of a protein from 
its amino acid sequence, using an existing crystal structure (template) for an 
evolutionary related protein (target) (Moult et al., 2014).  
Although homology modelling is a very reliable method and validated by CASP (see 
1.4), loop modelling in protein structure prediction can be challenging because 
alterations in loop conformations are hardly predicted in homology modelling (Jamroz 
and Kolinski, 2010). Loops are involved in structural and biological processes such 
as protein-protein interactions, signalling cascades and enzyme catalysis (Espadaler 
et al., 2006). Insertions and deletions occurs frequently at loop regions and turns 
than the conserved α-helix or β-sheets. Even without insertions or deletions, loops 
may induce a conformational change in a target protein due to involvement of the 
surface loops in crystal surface contact or exchange of a side chain in loop or either 
mutation of Pro or Gly residue (Krieger et al., 2003). Fortunately, loop modelling was 
easier in 3D model prediction of Cltx-like short toxins by using existing solved crystal 
structures of Cltx and Insectotoxin I5A from PDB-databank.  
Protein-protein docking is performed to investigate the interaction between two 
proteins or between a drug and a protein (Coelho et al., 2016). Recently, docking 
has been performed extensively to analyse binding affinities of a protein or a drug on 
its target molecule which provides useful information of enzyme-inhibitor interactions, 
drug design screen etc (Kozakov et al., 2013; Coelho et al., 2016). Although, few 
problems are generally associated with docking as predicted complexes may give an 
inaccurate binding sites of the target protein, screening using small molecule 
database and high binding affinity but failed subsequent MD (Chen et al., 2015). A 
ligand binding to its receptor do not clarify whether it is an agonist or an inhibitor 
hence some results may be validated by performing bioassays (Chen et al., 2015). 
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Therefore, homology modelling and docking are assessed by CASP and CAPRI 
experiments as mentioned in introduction section.  
ClusPro has been widely used in protein-protein docking in the past few years and 
results generated by this programme have been used in more than 400 publications 
(Kozakov et al., 2017). The results generated by ClusPro have been validated by 
experiments such as site-directed mutagenesis with NMR, calorimetry, FRET, or surface 
plasmon resonance, cross-linking, spectroscopy and X-ray scattering, electron self-
exchange reaction, radiolytic protein footprinting with mass spectrometry, 
hydrogen/deuterium exchange, or intermolecular NOE restraints (Sondermann et al., 
2005; Guzman et al., 2009; Man et al., 2010; Kozakov et al., 2017). ClusPro 
performs a global sampling search on a grid to produce highly populated clusters 
with lowest energy, this approach is useful if there is no prior knowledge of the 
interacting site or residues available for two proteins. It generates 1000 docked 
structures, clusters them and refine them by CHARMM minimisation to remove steric 
clashes and produces near-native structures (Kozakov et al., 2013).  
One major limitation of the programme is the rigid body assumption that limits the 
applicability of the programme (Kozakov et al., 2004). ClusPro docking programme 
considers ligand and receptor proteins as rigid body molecules and do not allow a 
conformational change in active site upon binding (Kozakov et al., 2007). MD 
simulation studies have shown that sometimes binding of a ligand to receptor may 
introduce a conformational change in the active site (Mobley et al., 2007). Protein-
protein docking benchmark also uses certain difficult bound complexes that allow 
conformational change in the backbone geometry upon binding. ClusPro or any other 
rigid body docking programme cannot provide acceptable solutions if this type of shift 
occurs upon binding (Kozakov et al., 2017). However, rigid body docking is useful in 
producing good acceptable solutions in many enzyme-inhibitor docking (Kozakov et 
al., 2007). Upon binding, enzyme-inhibitor complexes show a very small 
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conformational change in backbone geometry and restricted to side chains or loops 
(Kozakov et al., 2007).  However, neglecting a small conformational change can lead 
to errors in binding affinities which may jeopardise the accuracy of binding 
interactions (Mobley et al., 2007). Flexible docking programmes such as ROSETTA 
and HADDOCK allow conformational change between a ligand and receptor protein 
upon binding but are very time consuming and requires a priori knowledge and list of 
interacting residues. Since there is a very limited knowledge about Cltx interaction 
with its proposed putative binding partners, Rosetta and HADDOCK docking 
programmes are not useful in this study.  
Another limitation of the ClusPro is that the docking does not account for non-
standard or modified amino acids for example by phosphorylation. Furthermore, the 
docking may also experience difficulties for certain complexes when it comes to 
cofactors, which affects protein interactions. Although, continuous work is being 
carried out to remove these technical shortcomings soon (Xia et al., 2016; Kozakov 
et al., 2017). MD simulations are computationally expensive and requires an 
extensive computational throughput and generally performed at industry level 
(Mobley et al., 2009).  
ClusPro results can be used in laboratory validation experiments. Such combination 
of in-silico and laboratory studies can provide most meaningful use of docking. 
Enzyme assays can be performed in laboratories to study the interaction of Cltx and 
Cltx-like short toxins such as CA4 with MMP2. By using this method, the interaction 
of Cltx with different domains of MMP2 can be studied. Also, the activity of Cltx with 
the active site of MMP2 can be investigated. In addition, co-localisation studies can 
be performed to investigate interaction between fluorescently labelled Cltx or Cltx-like 
short toxins and MMP2 or AnxA2. Furthermore, MMP2 or AnxA2 knockout 
experiments can be performed to inhibit binding and interaction between Cltx and 
MMP2 or AnxA2.  
Page 101 of 125 
Single nucleotide polymorphism (SNP) variations of MMP2 can alter the interaction 
of Cltx and MMP2 on glioma cells which can affect cancer treatment. SNP variants of 
MMP2 can be produced in-silico and tested against Cltx to find binding affinity and 
the interaction of two molecules. In-silico screening of Cltx and Cltx-like short toxins 
against MMP2 SNP variants may provide a new therapeutic toxin that have higher 
binding affinity and greater efficacy. Computational screening of other Cltx-like short 
toxins may reveal a highly potent and more effective toxin in glioma treatment than 
Cltx. By using the knowledge of mutation, a better Cltx-like short toxin can be 
modelled computationally that have stronger binding. The design of the toxin can be 
used to improve Cltx interactions with MMP2, other MMPs and AnxA2 for effective 
glioma therapy. 
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7 APPENDIX. 
 
7.1 Quality of MMP2 Isoforms 
 
Fig 7.1.1 The quality assessment of 1CK7-A-. (a) QMEAN6 score of the native 
activated MMP2 (1CK7-A-) and identification of the score of individual geometrical 
features. (b) Z-Score of 1CK7-A- different shades of grey as black dots represent Z-
Scores of the reference structures located in the PDB-databank. The red star in the 
figure represents 1CK7-A- model. 
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  Fig 7.1.2  PROCHECK Ramachandran plot of 1CK7-A-. Ramachandran plot shows 
resdiues in the most favoured, yellow region  show residues in the allowed region, grey region 
show residues in the disallowed region, white region shows residues in the disallowed region. 
Glycine can be located in white regions as it does not contain a side chain.  
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Fig 7.1.3  The quality assessment of 1CK7 A-. (A) QMEAN6 score of the activated 
MMP2 (1CK7 A-) and identification of the score of individual geometrical features. (B) 
Z-Score of 1CK7 A- different shades of grey as black dots represent Z-Scores of the 
reference structures located in the PDB-databank and the red star represents 1CK7 
A- model. (C) Ramachandran plot shows resdiues in the most favoured, yellow 
region  show residues in the allowed region, grey region show residues in the 
disallowed region, white region shows residues in the disallowed region. Glycine can 
be located in white regions as it does not contain a side chain. 
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Fig 7.1.4 The quality assessment of 1CK7-. (A) QMEAN6 score of the native 
MMP2 (1CK7-) and identification of the score of individual geometrical features. (B) 
Z-Score of 1CK7- different shades of grey as black dots represent Z-Scores of the 
reference structures located in the PDB-databank and the red star represents 1CK7 -
. (C) Ramachandran plot shows resdiues in the most favoured, yellow region  show 
residues in the allowed region, grey region show residues in the disallowed region, 
white region shows residues in the disallowed region. Glycine can be located in white 
regions as it does not contain a side chain. 
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7.2  Quality of Chlorotoxin 
 
Fig 7.2.1 The quality assessment of chlorotoxin. (a) QMEAN6 score of 
chlorotoxin and identification of the score of individual geometrical features. 
QMEAN6 value of Cltx is 0.33 (b) Z-Score of Cltx, different shades of grey as black 
dots represent Z-Scores of the reference structures located in the PDB-databank 
and the red star represent Cltx. 
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  Fig 7.2.2 PROCHECK Ramachandran plot of chlorotoxin 3D strcutrue. Ramachandran 
plot shows resdiues in the most favoured, yellow region  show residues in the allowed region, 
grey region show residues in the disallowed region, white region shows residues in the 
disallowed region. Glycine can be located in white regions as it does not contain a side chain.  
  
Toxin QMEAN 6 Z-Score DFIRE % Residues 
in disallowed 
region 
Cltx 0.33 -1.561 -32.55 0 
CTX23 0.45 -0.916 -33 0 
CA4 0.61  -0.054 -32.37 0 
Cltx-like pep 
AaCTX 
0.75 0.706 -32 0 
 
Table 7.2.3 The quality assessment of 3D models of Cltx-like short toxins. QMEAN6 and 
Z-Score values of all four models are within an acceptable QMEAN range. All models have a 
low energy hence less steric clashes. All models are good structures and comparable to a set 
of experimentally determined 3D structures of similar sizes from PDB-databank. None of 
residues are in disallowed region in Ramachandran plot.  
 
Page 124 of 125 
 
Acknowledgement 
I would like to thank Dr. Kirsti Newton and Prof. Peter Strong, my thesis supervisors, 
for their academic supervision and support throughout all my years in Biomolecular 
Research Centre, as well as, Dr. Anne-Marie Harrison for her supervision at various 
stages during this project, for her invaluable advice and support.  
I wish to thank my parents and family for their support, encouragement and motivation 
during the work on my thesis.  
I also thank everyone in BMRC who have helped me during this research study. 
 
Page 125 of 125 
 
 
